[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 399
1. Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T, Nobuoka A, Kukitsu T, Kato J, Sakamaki S, Niitsu Y: Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol; 2001 Feb;36(2):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was placed, in turn, on a low-fat diet, an elemental diet, and, subsequently, fasting therapy with total parenteral nutrition (TPN) support.
  • On the 45th day of hospitalization, octreotide therapy was initiated.
  • After 2 weeks of treatment, his clinical symptoms, as well as hypoproteinemia and hypoalbuminemia, gradually became alleviated.
  • The improvement was confirmed in terms of scintigraphy, endoscopy, and histology of the duodenum.
  • The patient remained healthy until 6 months after the commencement of octreotide treatment, when he discontinued octreotide at his own discretion, at which point the symptoms recurred.
  • Resumption of the drug, however, again brought about remission, which has continued until the present, March 2000.
  • Thus, octreotide therapy is one modality which may be useful for refractory primary intestinal lymphangiectasia.
  • [MeSH-major] Gastrointestinal Agents / therapeutic use. Lymphangiectasis, Intestinal / drug therapy. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Lymphangiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2001 Feb;36(2):137-8 [11227672.001]
  • (PMID = 11227670.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


2. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology; 2000 Dec;141(12):4600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
  • Type 2 diabetes results either from primary beta-cell failure alone and/or a failure to secrete enough insulin to overcome insulin resistance.
  • Our current results in both young and old rats demonstrate that treatment caused an up-regulation of pancreatic-duodenum homeobox-1 (PDX-1) expression in islets and total pancreas, induced pancreatic cell proliferation, and beta-cell neogenesis.
  • PDX-1 protein levels increased 4-fold in whole pancreata and 6-fold in islets in response to treatment.
  • Therefore, GLP-1 would seem to be a unique therapy that can stimulate pancreatic cell proliferation and beta-cell differentiation in the pancreas of rodents.
  • [MeSH-major] Aging. Cell Division / drug effects. Glucagon / pharmacology. Glucose Intolerance. Islets of Langerhans / drug effects. Peptide Fragments / pharmacology. Protein Precursors / pharmacology. Trans-Activators / genetics
  • [MeSH-minor] Animals. Blood Glucose / analysis. Gene Expression Regulation / drug effects. Glucagon-Like Peptide 1. Homeodomain Proteins / genetics. Insulin / blood. Pancreas / cytology. Pancreas / drug effects. Pancreas / metabolism. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. GLUCAGON .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11108273.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Homeodomain Proteins; 0 / Insulin; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein; 89750-14-1 / Glucagon-Like Peptide 1; 9007-92-5 / Glucagon
  •  go-up   go-down


3. Sivri B: Trends in peptic ulcer pharmacotherapy. Fundam Clin Pharmacol; 2004 Feb;18(1):23-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in peptic ulcer pharmacotherapy.
  • Considering the diseases of the stomach and duodenum, peptic ulcer has been the one with a significant clinical impact.
  • Despite the decreasing frequency of H. pylori-induced peptic ulcers, peptic ulcer remains a major clinical problem partly because nonsteroidal anti-inflammatory drug (NSAID)-related ulcers and hospital admissions for ulcer complications associated with NSAIDs have increased in frequency.
  • [MeSH-major] Anti-Ulcer Agents / therapeutic use. Peptic Ulcer / drug therapy
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Helicobacter Infections / drug therapy. Helicobacter Infections / microbiology. Helicobacter pylori. Humans

  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14748750.001).
  • [ISSN] 0767-3981
  • [Journal-full-title] Fundamental & clinical pharmacology
  • [ISO-abbreviation] Fundam Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anti-Ulcer Agents
  • [Number-of-references] 64
  •  go-up   go-down


Advertisement
4. Padussis J, Loffredo B, McAneny D: Minimally invasive management of obstructive gastroduodenal tuberculosis. Am Surg; 2005 Aug;71(8):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the stomach and duodenum are involved in just 0.3-2.3% of TB cases that affect the gut.
  • Gastric outlet obstruction due to TB has been traditionally treated by a surgical bypass operation, followed by anti-TB chemotherapy.
  • [MeSH-major] Duodenum / surgery. Gastric Outlet Obstruction / surgery. Minimally Invasive Surgical Procedures. Stomach / surgery. Tuberculosis, Gastrointestinal / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Jejunostomy. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217956.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Vizer G, Bárány L, Baranyay F, Iványi JL: [Multiple lymphomatous polyposis--rare case of gastrointestinal hemorrhage]. Orv Hetil; 2001 May 20;142(20):1055-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The urgent upper gastrointestinal endoscopy revealed an ulcerated polypoid tumor in the region of angulus of the stomach, and multiple polypoid lesions in the bulbar part of the duodenum.
  • Computer tomography detected mesenterial, retroperitoneal and mediastinal lymph node involvement as well.
  • According to literature data this histological type of the gastrointestinal lymphoma has poor response to chemotherapy, the prognosis is unfavourable.
  • In this particular case the administered chemotherapy resulted in total remission at the lymphoma patient clinically staging III Ae.
  • In the proper follow-up examinations of the patient upper and lower endoscopy, histology samples, laboratory parameters, computer tomography, and physical examination in every 3 months are the methods.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Neoplasms / complications. Gastrointestinal Neoplasms / diagnosis. Lymphoma, Mantle-Cell / complications. Lymphoma, Mantle-Cell / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Colonic Polyps / complications. Colonic Polyps / diagnosis. Diagnosis, Differential. Duodenal Neoplasms / complications. Duodenal Neoplasms / diagnosis. Humans. Lymphatic Metastasis. Male. Middle Aged. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11407067.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Di Marco L, Berghenti M, Felloni M: [Primary adenocarcinoma of the second portion of duodenum]. Ann Ital Chir; 2003 Sep-Oct;74(5):573-6; discussion 576-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the second portion of duodenum].
  • [Transliterated title] Adenocarcinoma primitivo della II porzione duodenale.
  • The authors report a case of primary adenocarcinoma of the second portion of duodenum in a 56-years-old man radically managed by pancreaticoduodenectomy.
  • They remark the rarity of this pathology, the difficulty of making diagnosis peculiar to neoplasms of the small intestine and the difficulty of treatment peculiar to tumours of duodenum.
  • The possible therapy is surgical.
  • Radio and chemotherapy don't significantly improve survival.
  • Better results can be obtained only with an early diagnosis.
  • [MeSH-major] Adenocarcinoma. Duodenal Neoplasms
  • [MeSH-minor] Age Factors. Duodenum / pathology. Endoscopy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Pancreaticoduodenectomy. Sex Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139715.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Liu ZF, Jiao SC, Yang JL, Dai GH: [Clinical research of 120 cases of primary small intestine malignant tumor]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar;30(3):602-4, 607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research of 120 cases of primary small intestine malignant tumor].
  • OBJECTIVE: To study the clinical and pathological features, diagnosis, therapy and prognosis of primary small intestine malignant tumor.
  • METHODS: A retrospective analysis was performed on the clinical data from the 120 cases of primary small intestine malignant tumor.
  • Most tumors originated in the duodenum (54.1%), and adenocarcinoma (55.8%) was the main pathological type.
  • The median survival time of the patients was 19.2 months and the 1-year survival rate was 55.4%.
  • Chemotherapy did not seem to significantly improve the 1-year survival rate of the patients (P=0.842).
  • CONCLUSION: Primary small intestine malignant tumors lack specific clinical manifestations and surgical resection should be performed as early as possible.
  • [MeSH-major] Adenocarcinoma. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335150.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Mizuiri H, Yoshida K, Shimizu K, Tanabe K, Taomoto J, Suzuki T, Wada Y, Hihara J: [Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2043-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy].
  • The patient was a 58-year-old man who suffered from non-resectable gastric cancer, staged intraoperatively for peritoneal dissemination and paraaorta lymph node metastasis at another hospital in December 2002.
  • He was diagnosed with gastric cancer duodenum invasion, obstructive jaundice and lymphangitis carcinomatosa, and began weekly TXL as second-line chemotherapy on March 26.
  • One week after the first infusion therapy, the jaundice and dyspnea were greatly improved.
  • CT scan showed the lymphangitis carcinomatosa had disappeared and paraaorta lymph node metastasis was reduced to 60% after one cycle of the treatment.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Lymph Nodes / pathology. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Alopecia / chemically induced. Drug Administration Schedule. Duodenal Neoplasms / pathology. Humans. Jaundice, Obstructive / pathology. Leukopenia / chemically induced. Lymphangitis / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570937.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Wex T, Kuester D, Vieth M, Treiber G, Krieg A, Roessner A, Malfertheiner P: Helicobacter pylori infection and short-term intake of low-dose aspirin have different effects on alpha-1 antitrypsin/alpha-1 peptidase inhibitor (alpha1-PI) levels in antral mucosa and peripheral blood. Scand J Gastroenterol; 2008;43(10):1194-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Twenty volunteers (H. pylori-positive and -negative: n=10) received 2 x 50 mg aspirin/day for 7 days. H. pylori-positive subjects underwent eradication therapy and repeated the protocol.
  • Blood and tissue samples were obtained on days 0, 1, 3 and 7; alpha1-PI levels were determined by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and analyzed for histopathological findings.
  • RESULTS: Mucosal alpha1-PI expression was between 30 and 75 pg/10 microg total protein in H. pylori-negative subjects, and found to be similar in antral, corpus and duodenal mucosa.
  • In H. pylori-infected subjects, alpha1-PI levels were significantly increased in the antrum (mean: 111 versus 37.4 pg/10 microg protein; p=0.019), whereas corresponding levels in the corpus, duodenum and sera were unchanged.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Aspirin / administration & dosage. Gene Expression Regulation, Enzymologic / drug effects. Helicobacter Infections / metabolism. alpha 1-Antitrypsin / metabolism
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / microbiology. Gene Expression / drug effects. Helicobacter pylori. Humans. Male. Pyloric Antrum / chemistry. Reverse Transcriptase Polymerase Chain Reaction. Time Factors


10. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY: Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol; 2008 Aug;32(8):1130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal antibodies (mAbs) against the cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule are used as an adjuvant to experimental tumor immunization protocols in the treatment of malignant melanomas and ovarian cancers.
  • Aside from noted early therapeutic successes, a spectrum of adverse effects, including severe gastroenteritis, has been reported.
  • We report herein our observations of 5 patients who developed severe gastrointestinal toxicity affecting the gastric, small intestinal, and colonic mucosa.
  • Cryptitis and glandular inflammation were observed in the colon, ileum, and stomach, whereas villous blunting was present in the ileal and duodenal mucosa.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antigens, CD / immunology. Gastric Mucosa / drug effects. Gastroenteritis / chemically induced. Immunohistochemistry. Intestinal Mucosa / drug effects. Neoplasms / drug therapy. T-Lymphocyte Subsets / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Aged. CTLA-4 Antigen. Diarrhea / chemically induced. Diarrhea / immunology. Female. Humans. Male. Melanoma / drug therapy. Melanoma / immunology. Melanoma / pathology. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. Treatment Outcome


11. Oshiro A, Nagasaki A, Nakachi A, Uchima N, Hasegawa H, Nakazato T, Nakamoto M, Kinjo N, Kinjo F, Taira N, Masuda M, Takasu N: [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant lymphoma of the duodenum successfully treated with dose escalating chemotherapy].
  • A 65-year-old woman with diabetes mellitus was hospitalized for heart failure and anemia in August 2001, and recovered with conservative treatment.
  • An endoscopic examination revealed an ulcerative mass located in the duodenal bulb to the 2nd portion.
  • Abdominal CT scan demonstrated tumor involvement in the pancreas head.
  • The diagnosis of a diffuse large B-cell lymphoma, clinical stage IIE, was made by endoscopic biopsy.
  • Although surgical resection of the localized intestinal tumor would have been a common choice for initial treatment, polychemotherapy was selected; the patient had diabetes mellitus and preferred polychemotherapy to surgical operation.
  • Because of bulky intestinal mass, transmural disease and sensitive histological type, standard-dose chemotherapy was considered to include a high risk of intestinal perforation.
  • We performed dose-escalating chemotherapy: A half dose of THP-COP (pirarubicin, cyclophosphamide, vincristine) was given at the start in October 2001, 60% THP-COP as the next cycle, 80% THP-COP as the 3rd cycle and thereafter.
  • Without serious complications of the intestine, she received a total of 6 cycles of chemotherapy and subsequent involved field radiation.
  • There has been no evidence of recurrence of disease 14 months from the start of chemotherapy.
  • When conditions make surgical treatment difficult, dose-escalating chemotherapy in a treatment cycle may be considered as an alternative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Duodenal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


12. Darmani NA, Crim JL, Janoyan JJ, Abad J, Ramirez J: A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res; 2009 Jan 12;1248:40-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew.
  • Although the neurotransmitter basis of chemotherapy-induced vomiting (CIV) is thought to be multifactorial, it is generally accepted that acute (immediate) CIV is mainly due to the release of serotonin (5-HT) within the gastrointestinal tract, while the delayed phase occurs following substance P (SP) release in the brainstem.
  • Cisplatin (0, 5, 10 and 20 mg/kg, i.p.) caused dose- and time-dependent emetic effects.
  • A 10 mg/kg dose of cisplatin produced both phases of emesis with corresponding peak mean frequencies occurring at 2-3 and 33 h post-treatment, at 5 mg/kg it failed to cause significant emesis in either phase, while its 20 mg/kg dose induced both phases earlier but toxicity restricted the full 47 hour observation.
  • The discussed increases during both phases appear to be site specific since neurotransmitter release was not persistently altered in the shrew frontal cortex or duodenum, although occasionally increases or decreases did occur.
  • [MeSH-minor] Animals. Brain Stem / drug effects. Brain Stem / metabolism. Chromatography, High Pressure Liquid. Dopamine / metabolism. Dose-Response Relationship, Drug. Duodenum / drug effects. Duodenum / metabolism. Emetics. Female. Frontal Lobe / drug effects. Frontal Lobe / metabolism. Homovanillic Acid / metabolism. Male. Serotonin / metabolism. Shrews. Substance P / metabolism

  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022231.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA115331
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Emetics; 0 / Neurotransmitter Agents; 333DO1RDJY / Serotonin; 33507-63-0 / Substance P; Q20Q21Q62J / Cisplatin; VTD58H1Z2X / Dopamine; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


13. Deixler E, Helmke K: [Extrahepatic cholestasia during therapy with Zolmitriptan (AscoTop)]. Z Gastroenterol; 2005 Sep;43(9):1045-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrahepatic cholestasia during therapy with Zolmitriptan (AscoTop)].
  • [Transliterated title] Extrahepatische Cholestase unter Therapie mit Zolmitriptan (Asco-Top).
  • Because of recurrent abdominal pain, jaundice and elevated liver function tests, a sixty-two-year old man had been referred to hospital several times within the preceding six months.
  • Quantitative hepatobiliary scintigraphy demonstrated retention of activity in the intra- and extrahepatic bile ducts and delayed transit of activity to the duodenum as signs of papillary dysfunction.
  • Drug anamnesis revealed that the patient had started migraine treatment with Zolmitiptan, a 5-HT (1B/1D)-receptor agonist of the second generation, six months before the beginning of the cholestasia syndrome.
  • Because of the known increase in amplitudes of oesophageal motor waves and of lower oesophageal sphincter tone by Sumatriptan, a 5-HT (1B/1D)-receptor agonist of the first generation, Zolmitriptan treatment was stopped.
  • Thus it is not surprising that therapeutic measures which influence the serotoninergic system in the CNS are also effective in the enteric nervous.
  • [MeSH-major] Bile Ducts, Extrahepatic / radionuclide imaging. Cholestasis, Extrahepatic / chemically induced. Cholestasis, Extrahepatic / diagnosis. Oxazolidinones / adverse effects
  • [MeSH-minor] Humans. Male. Middle Aged. Migraine Disorders / drug therapy. Serotonin Receptor Agonists / adverse effects. Serotonin Receptor Agonists / therapeutic use. Tryptamines

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142613.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Oxazolidinones; 0 / Serotonin Receptor Agonists; 0 / Tryptamines; 2FS66TH3YW / zolmitriptan
  •  go-up   go-down


14. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Small intestine cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis; 2009;4:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FAP has an incidence at birth of about 1/8,300, it manifests equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases.
  • Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops.
  • A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk.
  • Most patients (~70%) have a family history of colorectal polyps and cancer.
  • Diagnosis is based on a suggestive family history, clinical findings, and large bowel endoscopy or full colonoscopy.
  • Whenever possible, the clinical diagnosis should be confirmed by genetic testing.
  • Cancer prevention and maintaining a good quality of life are the main goals of management and regular and systematic follow-up and supportive care should be offered to all patients.
  • By the late teens or early twenties, colorectal cancer prophylactic surgery is advocated.
  • Duodenal cancer and desmoids are the two main causes of mortality after total colectomy, they need to be identified early and treated.
  • Upper endoscopy is necessary for surveillance to reduce the risk of ampullary and duodenal cancer.
  • Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform).
  • Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP.
  • Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):543-8 [7959691.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Am Fam Physician. 1995 Sep 15;52(4):1210 [7668210.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):769-70 [8696735.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):885-92 [8813770.001]
  • [Cites] J Med Genet. 1996 Jul;33(7):540-3 [8818937.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1578-80 [9014679.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):514-9; discussion 519-21 [9351719.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):431-5 [9487968.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):736-7 [9497250.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):353-60 [10207640.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):902-9 [10441594.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 15;27(18):3638-44 [10471731.001]
  • [Cites] Fam Cancer. 2006;5(3):213-20 [16998666.001]
  • [Cites] Fam Cancer. 2006;5(3):227-35 [16998668.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Fam Cancer. 2006;5(3):275-85; discussion 287-8 [16998673.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Genet Med. 2006 Nov;8(11):697-703 [17108761.001]
  • [Cites] Reprod Biomed Online. 2006 Nov;13(5):707-11 [17169185.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):95-101 [17114207.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1284-90 [17355417.001]
  • [Cites] Hum Mutat. 2007 Oct;28(10):985-92 [17486639.001]
  • [Cites] Genet Test. 2007 Fall;11(3):315-20 [17949294.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5 [18237868.001]
  • [Cites] Fam Cancer. 2008;7(1):27-39 [17999161.001]
  • [Cites] Gut. 2008 May;57(5):704-13 [18194984.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Endoscopy. 2008 May;40(5):437-42 [18398783.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):741-8 [18436175.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1132-40 [18487285.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2404-10 [18706807.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] J Pediatr. 1999 Sep;135(3):390-5 [10484811.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Am J Hum Genet. 1955 Sep;7(3):236-63 [13258558.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] Genet Test. 2004 Winter;8(4):421-30 [15684875.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):212-4 [15690400.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1077-80 [15825088.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1528-34 [15906134.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83 [16042573.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):312-4 [16492921.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):407-17 [16511903.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 15;28(6):1355-64 [10684930.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):893-8; discussion 898-902 [10910233.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):747-54 [10980114.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1454-60 [11113066.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):597-602 [11296028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):121-5 [11316554.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • [Cites] J Wound Ostomy Continence Nurs. 2001 Jul;28(4):184-9 [11452254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):664 [12007223.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3565-71 [12354847.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):227-31 [12555301.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):481-5 [12682541.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1574-94 [12761718.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Fam Cancer. 2001;1(2):75-82 [14574001.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] Genet Test. 2003 Fall;7(3):189-94 [14641994.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):655-6 [14961559.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6820-2 [15273732.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):838-44 [15362039.001]
  • [Cites] Acta Chir Scand. 1975;141(3):228-37 [1166747.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):290-6 [3422541.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Ann Med. 1989 Aug;21(4):299-307 [2551351.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1658-64 [1673441.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):33-45 [8317496.001]
  • (PMID = 19822006.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2772987
  •  go-up   go-down


16. Li XB, Ge ZZ, Chen XY, Liu WZ: Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis. Braz J Med Biol Res; 2007 Jul;40(7):897-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis.
  • Whether the regression of gastric metaplasia in the duodenum can be achieved after eradication of Helicobacter pylori is not clear.
  • Eighty-six patients with endoscopically confirmed nodular duodenitis and 40 control patients with normal duodenal appearance were investigated.
  • The H. pylori-positive patients with duodenitis received anti-H. pylori triple therapy (20 mg omeprazole plus 250 mg clarithromycin and 400 mg metronidazole, all twice daily) for one week.
  • A control endoscopy was performed 6 months after H. pylori treatment.
  • The H. pylori-negative patients with duodenitis received 20 mg omeprazole once daily for 6 months and a control endoscopy was performed 2 weeks after treatment.
  • No influence on the endoscopic appearance of nodular duodenitis was found after eradication of H. pylori or acid suppression therapy.
  • Only mild chronic inflammation, but not gastric metaplasia, was found in the control group, none with H. pylori infection in the duodenal bulb.
  • Therefore, H. pylori infection is related to the extent of gastric metaplasia in the duodenum, but not to the presence of diffuse nodular duodenitis.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653441.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 140QMO216E / Metronidazole; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


17. Xie Y, Xuan ZY, Yu L, Guo J: [Effects of Shujing Ketong soft capsules on uterine activity of animals]. Zhongguo Zhong Yao Za Zhi; 2008 Jun;33(12):1466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2, 38.4 mg x kg(-1) of SJKTSC and 2 g x kg(-1) of Tongjingbao granules were given to the rat through the duodenum respectively.
  • CONCLUSION: Shujing Ketong soft capsules maybe used for treatment of dysmenorrhea induced by spasm of uterine smooth muscle.
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Uterine Contraction / drug effects. Uterus / drug effects. Uterus / physiology
  • [MeSH-minor] Animals. Capsules. Dose-Response Relationship, Drug. Dysmenorrhea / drug therapy. Dysmenorrhea / physiopathology. Female. In Vitro Techniques. Muscle, Smooth / drug effects. Muscle, Smooth / physiology. Oxytocin / adverse effects. Rats. Rats, Wistar. Time Factors

  • Hazardous Substances Data Bank. Oxytocin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837358.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Capsules; 0 / Drugs, Chinese Herbal; 0 / shujing ketong; 50-56-6 / Oxytocin
  •  go-up   go-down


18. Sentani K, Maeshima AM, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases. Jpn J Clin Oncol; 2008 Aug;38(8):547-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases.
  • OBJECTIVE: Follicular lymphomas (FLs) occur commonly in the lymph nodes, and duodenal FL (DFL) is reported to be rare.
  • Primary DFLs and systemic FLs that involved the duodenum at any point during the clinical course were included in the analysis.
  • RESULTS: Typically, primary DFLs (14 cases) were found incidentally at routine medical check-ups, whereas involvement of the duodenum by systemic FLs (12 cases) was found through staging procedures.
  • All cases involved the second portion of the duodenum.
  • Treatment regimens employed were rituximab (R) plus chemotherapy (10), R (6), chemotherapy (3), irradiation (3) and the other three patients were subjected to observation.
  • The duodenum appears to be a frequently involved extranodal site of FL with IGH/BCL2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / pathology. Lymphoma, Follicular / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / therapy. Proto-Oncogene Proteins c-bcl-2 / genetics. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687756.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


19. Sumi M, Tauchi T, Sashida G, Kuriyama Y, Nakajima A, Mukai K, Ohyashiki K: Natural killer cell lymphoma in the duodenum. Leuk Lymphoma; 2003 Jan;44(1):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell lymphoma in the duodenum.
  • We present a case of duodenal non-Hodgkin lymphoma in a 71-year-old woman.
  • She was treated with intensive chemotherapy including pirarubicin, cyclophosphamide, vincristine, and prednisolone, but died three weeks after diagnosis.
  • CD56(+) lymphomas originate from NK or cytotoxic T cells and are designated "extranodal NK/T-cell lymphoma, nasal type" in the WHO classification.
  • Extranodal NK/T-cell lymphoma, nasal type, is characterized by a broad morphologic spectrum and have variable prognosis.
  • [MeSH-major] Duodenal Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Fever / etiology. Humans. Immunohistochemistry. Immunophenotyping. Karyotyping. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Pain / etiology. Treatment Failure

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691165.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Thangapazham RL, Sharma A, Maheshwari RK: Beneficial role of curcumin in skin diseases. Adv Exp Med Biol; 2007;595:343-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The varied biological properties of curcumin and lack of toxicity even when administered at higher doses makes it attractive to explore its use in various disorders like tumors of skin, colon, duodenum, pancreas, breast and other skin diseases.
  • This chapter reviews the data on the use of curcumin for the chemoprevention and treatment of various skin diseases like scleroderma, psoriasis and skin cancer.
  • Curcumin treatment also reduced wound-healing time, improved collagen deposition and increased fibroblast and vascular density in wounds thereby enhancing both normal and impaired wound-healing.
  • These studies suggest the beneficial effects of curcumin and the potential of this compound to be developed as a potent nontoxic agent for treating skin diseases.
  • [MeSH-major] Curcumin / therapeutic use. Phytotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Animals. Humans. Models, Biological. Skin Neoplasms / drug therapy. Wound Healing / drug effects. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CURCUMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569219.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / G174KT
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] IT942ZTH98 / Curcumin
  • [Number-of-references] 78
  •  go-up   go-down


21. Pellicano R, De Angelis C, Resegotti A, Rizzetto M: Zollinger-Ellison syndrome in 2006: concepts from a clinical point of view. Panminerva Med; 2006 Mar;48(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Zollinger-Ellison syndrome (ZES) is characterised by peptic ulcers of the upper gastrointestinal tract failing to heal despite maximal medical therapy, diarrhoea and marked gastric acid hypersecretion associated with a gastrin-secreting tumour (gastrinoma).
  • ZES might be associated with multiple endocrine neoplasia type 1.
  • Somatostatin receptor scintigraphy is capable to localise the tumour in 80% of the cases and to identify it even in anatomic sites other than pancreas and duodenum.
  • The 2 main principal therapeutic strategies are to control both the gastric acid hypersecretion and the growth of the neoplasia.
  • Proton pump inhibitors (PPIs) are the drugs of choice for patients with ZES.
  • Furthermore, safety of PPIs in the maintenance therapy has been proven both in short- and in long-term studies.
  • The best surgical treatment is excision of gastrinoma before metastatic spread has occurred.
  • Chemotherapy, interferon and embolisation are indicated in rapidly evolving tumours or in cases in which the tumoral symptoms cannot be treated by other approaches.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Embolization, Therapeutic. Gastric Acid / secretion. Gastrinoma / surgery. Gastrins / secretion. Humans. Interferons / therapeutic use. Prognosis. Proton Pump Inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • Genetic Alliance. consumer health - Zollinger-Ellison syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633330.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gastrins; 0 / Proton Pump Inhibitors; 51110-01-1 / Somatostatin; 9008-11-1 / Interferons
  • [Number-of-references] 47
  •  go-up   go-down


22. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.


23. Hamblin MR, Viveiros J, Yang C, Ahmadi A, Ganz RA, Tolkoff MJ: Helicobacter pylori accumulates photoactive porphyrins and is killed by visible light. Antimicrob Agents Chemother; 2005 Jul;49(7):2822-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori colonizes the mucus layer of the human stomach and duodenum, causes chronic gastritis, gastric ulcer, and is a risk factor for gastric adenocarcinoma.
  • There is a 20% failure rate in antibiotic therapy, which is increasingly due to antibiotic resistance and necessitates the search for alternative antimicrobial methods.
  • Both virulent and drug-resistant strains are killed.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1979 Apr 15;180(1):45-50 [39545.001]
  • [Cites] Photochem Photobiol Sci. 2004 May;3(5):436-50 [15122361.001]
  • [Cites] Z Naturforsch C. 1986 Sep-Oct;41(9-10):867-72 [2948330.001]
  • [Cites] J Med Microbiol. 1990 Sep;33(1):29-34 [2231670.001]
  • [Cites] FEMS Immunol Med Microbiol. 1993 Mar;6(2-3):89-96 [8100161.001]
  • [Cites] J Photochem Photobiol B. 1993 Sep;20(1):47-54 [8229468.001]
  • [Cites] Photochem Photobiol. 1995 Apr;61(4):410-3 [7740086.001]
  • [Cites] Ann Med. 1995 Oct;27(5):589-94 [8541037.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jun 25;223(3):578-82 [8687438.001]
  • [Cites] J Photochem Photobiol B. 1996 Jul;34(2-3):123-8 [8810530.001]
  • [Cites] Scand J Gastroenterol Suppl. 1996;220:3-9 [8898429.001]
  • [Cites] J Photochem Photobiol B. 1997 May;39(1):1-18 [9210318.001]
  • [Cites] Clin Microbiol Rev. 1997 Oct;10(4):720-41 [9336670.001]
  • [Cites] Biotechniques. 1997 Oct;23(4):648-50 [9343684.001]
  • [Cites] FEMS Microbiol Lett. 1998 May 15;162(2):227-33 [9627957.001]
  • [Cites] APMIS. 1998 May;106(5):571-9 [9674895.001]
  • [Cites] Infect Immun. 2000 Jun;68(6):3193-9 [10816463.001]
  • [Cites] Arch Dermatol Res. 2000 Jun;292(6):320-2 [10929774.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Nov;46(7):1297-303 [11075959.001]
  • [Cites] Int J Med Microbiol. 2001 May;291(2):131-43 [11437336.001]
  • [Cites] Annu Rev Microbiol. 2001;55:165-99 [11544353.001]
  • [Cites] J Nutr. 2001 Oct;131(10):2789S-2793S [11584108.001]
  • [Cites] J Clin Laser Med Surg. 2002 Feb;20(1):3-7 [11902352.001]
  • [Cites] Lasers Surg Med. 2002;31(1):18-22 [12124710.001]
  • [Cites] Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S17-21 [12173103.001]
  • [Cites] J Infect. 2003 Jan;46(1):49-55 [12504609.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):17-24 [12589953.001]
  • [Cites] Aliment Pharmacol Ther. 2003 May 1;17(9):1137-43 [12752350.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jun 1;17(11):1333-43 [12786627.001]
  • [Cites] J Cosmet Laser Ther. 2003 Jun;5(2):111-7 [12850803.001]
  • [Cites] J Appl Bacteriol. 1986 Feb;60(2):121-6 [2871006.001]
  • (PMID = 15980355.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI050875; United States / NIAID NIH HHS / AI / R01 AI050875-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coproporphyrins; 0 / Culture Media; 0 / Photosensitizing Agents; 0 / Protoporphyrins
  • [Other-IDs] NLM/ PMC1168670
  •  go-up   go-down


24. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Ileum was the most commonly involved site (8 of 14 patients, 57.1%), followed by jejunum (2 of 14 patients, 14.3%) and duodenum (1 of 14 patients, 7.1%).
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Bhandarwar AH, Utture SS, Nandu B, Agarkhedkar N: Primary extra-ampullary duodenal neuroendocrine carcinoma in an adult male. Dig Endosc; 2009 Jul;21(3):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extra-ampullary duodenal neuroendocrine carcinoma in an adult male.
  • A primary extra-ampullary duodenal neuroendocrine carcinoma was found in a 40-year-old man who presented with upper abdominal pain and weight loss.
  • Duodenoscopy and hypotonic duodenography revealed a protruding fungating mass with luminal occlusion at the third part of the duodenum (D3).
  • Although the metastatic work-up was normal, the tumor was inoperable intraoperatively, hence a palliative bypass was carried out followed by chemotherapy with 5-fluorouracil and leucovorin.
  • The present case emphasizes the need for better detection, further analysis and evaluation of such rare cases to identify their clinical course and effective treatment modalities.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Duodenal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691767.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


26. Spiller R: Serotonin and GI clinical disorders. Neuropharmacology; 2008 Nov;55(6):1072-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EC cells are located in the gut mucosa with maximal numbers in the duodenum and rectum where they act as signal transducers, responding to pressure and luminal substances both bacterial and dietary.
  • These drugs also inhibit the nausea and vomiting occurring in patients undergoing chemotherapy which cause a marked increase in release of 5-HT as well as other mediators.
  • [MeSH-major] Gastrointestinal Diseases / drug therapy. Serotonin / metabolism. Serotonin Agents / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687345.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Serotonin Agents; 0 / Serotonin Plasma Membrane Transport Proteins; 333DO1RDJY / Serotonin
  • [Number-of-references] 119
  •  go-up   go-down


27. Penna Ch: [Management of familial polyposis coli]. J Chir (Paris); 2002 Oct;139(5):260-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge chirurgicale de la polypose adénomateuse familiale.
  • Familial Multiple Polyposis Coli is an autosomal dominant hereditary illness characterized by the appearance in childhood of hundreds of colorectal polyps which inexorably undergo malignant transformation.
  • Subtotal Colectomy with ileorectal anastomosis is a well-tolerated procedure with quite acceptable functional results, but the need for eventual proctectomy is about 30% at 20 years and the risk of rectal cancer is about 10% at 20 years even with close endoscopic surveillance.
  • NSAID's, tamoxifen, and chemotherapy are used preventively and therapeutically; surgical excision is sometimes required.
  • Duodenal adenomas are present in almost 100% of these patients post-colectomy and the risk of duodenal cancer is 200 times higher than in the general population.
  • Endoscopic surveillance of the duodenum is essential and prophylactic duodenal resection should be considered when duodenal polyposis is extensive.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / etiology. Adenoma / surgery. Adult. Anal Canal / surgery. Anastomosis, Surgical. Child. Colonic Pouches. Duodenal Neoplasms / diagnosis. Duodenal Neoplasms / etiology. Duodenal Neoplasms / surgery. Endoscopy. Fibromatosis, Abdominal / surgery. Follow-Up Studies. Humans. Intestinal Obstruction / surgery. Pancreaticoduodenectomy. Rectal Neoplasms / etiology. Rectal Neoplasms / surgery. Rectum / surgery. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12410125.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 29
  •  go-up   go-down


28. Ota K, Yamamoto T, Matsumura T, Fukunaga M, Ohzato H, Miwa H, Furukawa H: [A case of surgical treatment of solitary liver metastasis from pancreatic cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2407-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of surgical treatment of solitary liver metastasis from pancreatic cancer].
  • We report a 50-year-old female with pancreatic cancer invading the duodenum.
  • The postoperative irradiation to pancreatic bed was performed one month after surgery, followed by an adjuvant chemotherapy using gemcitabine.
  • Eight months post operation, CT examination showed liver and lung metastases, resulting in conversion of the drug to S-1.
  • CT revealed disappearance of recurrence during 7 months without any chemotherapy.


29. Sekita Y, Takeshita K, Tani M, Okamura N, Chida T, Kawano T, Iwai T: Microbiological evaluation after gastrectomy and reconstruction for gastric cancer. Int Surg; 2007 Nov-Dec;92(6):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbiological evaluation after gastrectomy and reconstruction for gastric cancer.
  • The purpose of this study was to evaluate microbial flora in the mucosa of reconstructed organs after gastrectomy for gastric cancer and improve postoperative quality of life by treating the flora.
  • The number of aerobes was significantly higher in the gastric remnant in the proximal gastrectomy-jejunal pouch interposition group (n=8) than the distal gastrectomy-Billroth II reconstruction (G-BII) group (n=2) or the pylorus-preserving gastrectomy (PPG) group (n=8).
  • However, the gastric remnant and duodenum in the distal gastrectomy-Billroth I reconstruction group (n=5; positive rate of 80% and 20%, respectively) and the PPG group (positive rate of 63% and 25%, respectively) showed H. pylori.
  • [MeSH-major] Bacterial Infections / drug therapy. Bacterial Infections / microbiology. Gastrectomy / adverse effects. Gastric Mucosa / microbiology. Gastroenterostomy / adverse effects. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bacteria, Aerobic. Bacteria, Anaerobic. Female. Halitosis / drug therapy. Halitosis / microbiology. Humans. Male. Middle Aged. Quality of Life

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402131.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS: Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res; 2005 Feb;15(1):72-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats.
  • We investigated the effects of IGF-I pre-treatment on chemotherapy-induced mucositis in rats.
  • 5-FU decreased villus height in the duodenum (23%), jejunum (20%) and ileum (30%) with crypt depths decreased by 31%, 27% and 33% in these gut regions.
  • These effects were less profound in IGF-I pre-treated rats in which apoptosis was increased 48-fold, with SI length decreased by 7%, SI weight by 18% and total gut weight by 15% accompanied by decreases in villus height of 8% (duodenum), 14% (jejunum) and 21% (ileum), and crypt depth decreases of 23%, 16% and 17% for the same gut regions, compared to normal controls.
  • We conclude that IGF-I pre-treatment only partially attenuates features of intestinal mucositis when assessed 48 h after 5-FU chemotherapy.
  • [MeSH-major] Fluorouracil / pharmacology. Inflammation / chemically induced. Insulin-Like Growth Factor I / pharmacology. Insulin-Like Growth Factor I / physiology. Intestinal Mucosa / drug effects
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / pharmacology. Apoptosis. Body Weight / drug effects. Bromodeoxyuridine / pharmacology. Cell Proliferation. Coloring Agents / pharmacology. Duodenum / drug effects. Ileum / drug effects. Intestine, Small / metabolism. Jejunum / drug effects. Male. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Sucrase / metabolism. Sucrose / pharmacology. Time Factors

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. SUCROSE .
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701575.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Coloring Agents; 57-50-1 / Sucrose; 67763-96-6 / Insulin-Like Growth Factor I; EC 3.2.1.48 / Sucrase; G34N38R2N1 / Bromodeoxyuridine; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Ishizaki M, Akiyama N, Tanaka S, Motegi M, Sasamoto H, Osawa H, Wada W, Nakajima M: [Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2001 Mar;28(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
  • A 58-year-old man was diagnosed as having advanced gallbladder cancer (T4, P0, H0, N0, stage IVa) with direct invasion to the liver, transverse colon and duodenum.
  • Therefore, extended cholecystectomy and bile duct resection with a partial resection of the transverse colon and the duodenum were performed in March 1992.
  • Repeated hepatic arterial infusion chemotherapy with 5-FU 500 mg/body/w, MMC 4 mg/body/2w and EPI 40 mg/body/4w was performed starting in January 1996.
  • Four months later, the lesions in the liver were reduced in size, and abdominal CT 10 months after the chemotherapy showed a partial response.
  • Repeated hepatic arterial infusion chemotherapy with the same regimen was performed again starting in March 1998.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gallbladder Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Colonic Neoplasms / secondary. Duodenal Neoplasms / secondary. Epirubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11265412.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Sakamoto K, Tashiro Y, Niwa K, Ono S, Ishiyama S, Sugimoto K, Kamiyama H, Komiyama H, Takahashi M, Kojima Y, Tomiki Y, Ichikawa J: [A case of duodenal perforation during mFOLFOX6 treatment for metastatic sigmoid colon cancer]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2925-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of duodenal perforation during mFOLFOX6 treatment for metastatic sigmoid colon cancer].
  • We present a case of metastatic sigmoid colon cancer causing duodenal perforation during modified FOLFOX6 chemotherapy.
  • The patient was a 68-year-old man who underwent sigmoidectomy for an advanced sigmoid cancer in September 2007.
  • He has been received mFOLFOX6 chemotherapy for multiple liver metastases since January 2009.
  • In March 2010, the patient complained of abdominal pain during the 24th course of chemotherapy, and was admitted to our hospital.
  • It ceased on the 25th admission day, and an upper gastrointestinal examination showed good passage of fluids and no leakage at the duodenum.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Diseases / etiology. Intestinal Perforation / etiology. Sigmoid Neoplasms / complications. Sigmoid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160272.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


33. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • Anderson Cancer Center between 1990 and 2008.
  • RESULTS: Median age was 55 years and primary tumor site was duodenum in 67%, jejunum in 20%, and ileum in 13%.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Nord C, Fosså SD, Giercksky KE: Gastrointestinal presentation of germ cell malignancy. Eur Urol; 2000 Dec;38(6):721-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 4 patients the duodenum and in 1 patient the distal part of the esophagus were involved in germ cell malignancy.
  • This patient and 2 other cases needed emergency surgery due to GI hemorrhage before and/or during the initial phase of chemotherapy.
  • Our observations compare well with the literature, showing the need of multimodality therapy of these complications.
  • CONCLUSION: In young males with a malignant tumor in the upper GI tract, the diagnosis of germ cell malignancy should be considered.
  • Treatment of this condition requires a multimodality approach, not rarely including emergency surgery.
  • Though these patients often belong to a poor-prognosis group, our results and the literature review show that long-term survival is possible using modern treatment principles.
  • In particular, the risk of GI hemorrhage, during the initial phase of therapy, should not be overseen.
  • [MeSH-major] Gastrointestinal Neoplasms / secondary. Germinoma / diagnosis. Testicular Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11111190.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Number-of-references] 10
  •  go-up   go-down


35. Ohara M, Tomoda F, Nakagawa T, Masutani T, Liu H, Ichikawa K, Hirose M, Koike T, Kagitani S, Inoue H: [Autopsy case of Henoch-Schönlein purpura nephritis complicated with intestinal cytomegalovirus infection]. Nihon Jinzo Gakkai Shi; 2010;52(8):1037-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on these findings, he was diagnosed as having Henoch-Schönlein purpura nephritis and steroid therapy was started.
  • Following steroid therapy, his nephrotic state remained unchanged, although his renal function improved concomitantly with the disappearance of arthralgia, purpura and abdominal symptoms.
  • Therefore, cyclosporine was added to the steroid therapy to enhance immunosuppression.
  • Endoscopy revealed multiple ulcers in the duodenum and jejunum, and clipping was performed at some bleeding sites.
  • The autopsy revealed that hemorrhagic lesions having cytomegalovirus infection spread widely in the stomach, duodenum and jejunum.
  • Recurrence of gastrointestinal bleeding during the treatment of Henoch-Schönlein purpura nephritis is usually due to severe vasculitis or steroid ulcer.
  • However, in patients receiving strong immunosuppressive therapy, cytomegalovirus infection needs to be considered as cause of gastrointestinal bleeding.
  • [MeSH-major] Colitis / virology. Cyclosporine / adverse effects. Cytomegalovirus Infections. Gastrointestinal Hemorrhage / etiology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Nephritis / complications. Nephritis / drug therapy. Purpura, Schoenlein-Henoch / complications. Purpura, Schoenlein-Henoch / drug therapy
  • [MeSH-minor] Autopsy. Drug Therapy, Combination. Fatal Outcome. Gastrointestinal Tract / pathology. Humans. Male. Middle Aged. Prednisolone / administration & dosage


36. Vakhrushev IaM, Potapova LO, Muravtseva OV: [How to raise efficacy of gastroesophageal reflux disease treatment]. Ter Arkh; 2009;81(2):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How to raise efficacy of gastroesophageal reflux disease treatment].
  • AIM: To specify dysfunction of the stomach and duodenum in gastroesophageal reflux disease (GRD) to offer more effective pathogenetic pharmacotherapy of GRD.
  • Addition of domperidon and mebeverin to routine combined treatment of GRD raises clinical efficacy of GRD treatment and promotes recovery of gastric and duodenal function though therapeutic efficacy of the above drugs depended on concomitant pathology.
  • CONCLUSION: Domperidon and mebeverin addition to combined treatment of GRD makes this treatment more effective.
  • [MeSH-major] Domperidone / therapeutic use. Gastroesophageal Reflux / drug therapy. Parasympatholytics / therapeutic use. Phenethylamines / therapeutic use. Proton Pump Inhibitors / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Therapy, Combination. Esophageal pH Monitoring. Female. Gastric Acidity Determination. Gastric Emptying / drug effects. Gastric Emptying / physiology. Humans. Hydrogen-Ion Concentration. Male. Manometry. Middle Aged. Myoelectric Complex, Migrating / drug effects. Myoelectric Complex, Migrating / physiology. Stomach / drug effects. Stomach / physiopathology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19334485.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Parasympatholytics; 0 / Phenethylamines; 0 / Proton Pump Inhibitors; 5587267Z69 / Domperidone; 7F80CC3NNV / mebeverine
  •  go-up   go-down


37. Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, Mallas E, Safioleas M: Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology; 2005 May-Jun;52(63):731-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
  • The primary tumors originated from the GI tract in 97/101 pts (appendix 34%, small intestine 31%, stomach 14%, duodenum 6%, colon 6%, rectum 3%) and from the pancreas in 4/101 (4%).
  • The diagnosis was confirmed histologically in all cases, after surgical excision of the primary tumor or by biopsies taken during endoscopy.
  • All pts were evaluated several times per year with clinical, biochemical and imaging assessments, including neuroendocrine markers [urinary 5-Hydroxyindoleacetic acid (5-HIAA), serum Chromogranin-A (CgA)] and Somatostatin Receptor Scintigraphy (OCTREOSCAN).
  • The follow-up period ranged between 1.5 to 12.5 years (mean time: 5 years and 3 months) and it is still in progress.
  • Furthermore, it revealed the primary and the metastatic lesions in 16% and 33% of pts with carcinoids of the small intestine respectively, while other conventional imaging procedures (including MRI) were negative at the same time.
  • Seventy-four percent of the pts underwent a surgical resection of the primary tumor, while in 21%, an endoscopic polypectomy was performed.
  • All pts with metastatic tumors and positive OCTREOSCAN, were treated with Somatostatin analogues, which resulted in control of symptoms (75%), stabilization of tumor growth (71%) or tumor shrinkage (9%).
  • A combined therapy with the addition of interferon-a was initiated in pts in whom, despite the increase of drug dosage and the shortening of administration intervals, a complete clinical and biochemical response was no more achieved with Somatostatin analogues alone.
  • CONCLUSIONS: a) Tumor size (especially in appendiceal and gastric carcinoids) and, also, the dispersion of disease, highly predict the evolution of the patients;.
  • b) serum Chromogranin-A seems to be a very useful tumor marker for the diagnosis and follow-up of pts with GI carcinoids;.
  • c) the introduction of new imaging techniques and especially OCTREOSCAN contributes to a better localization of the primary tumors and their metastases, as well as, to the right decision of the appropriate medical treatment;.
  • d) surgical excision is the treatment of choice in nonmetastatic tumors; and e) in pts with metastatic disease, the administration of Somatostatin analogues improves their quality of life.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoid Tumor / diagnosis. Chromogranins / blood. Gastrointestinal Neoplasms / diagnosis. Receptors, Somatostatin / blood. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966194.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CHGA protein, human; 0 / Chromogranin A; 0 / Chromogranins; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 54-16-0 / Hydroxyindoleacetic Acid; G083B71P98 / pentetreotide
  •  go-up   go-down


38. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • Distal gastrectomy with D2 dissection was performed.
  • However, at the resected organ, the lesion was on the duodenum.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.
  • But, we dosed down with S-1 due to severe diarrhea.
  • In spite of combined S-1 and CPT-11 chemotherapy, the CEA level increased, and lymph nodes were getting larger.
  • She then underwent the paclitaxel chemotherapy during the 5 months without severe side effects.
  • Paclitaxel chemotherapy is effective for duodenal cancer.
  • [MeSH-major] Duodenal Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Carnitine O-Palmitoyltransferase / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


39. Vithayasai N, Jennuvat S: Gastrointestinal manifestations in severe strongyloidiasis: report of 3 cases and literature review. Southeast Asian J Trop Med Public Health; 2010 Jan;41(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second and third patients were immunocompromised due to steroid and chemotherapy treatment of underlying diseases.
  • In all three cases, Strongyloides stercoralis larvae were detected in stool concentration samples, and in biopsied specimens from the duodenum in the first and second cases.

  • Genetic Alliance. consumer health - Strongyloidiasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578478.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


40. Coleman NS, Marciani L, Blackshaw E, Wright J, Parker M, Yano T, Yamazaki S, Chan PQ, Wilde K, Gowland PA, Perkins AC, Spiller RC: Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther; 2003 Nov 15;18(10):1039-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although 5-HT3 antagonists have been used to treat chemotherapy-induced emesis and diarrhoea-predominant irritable bowel syndrome, the effects of 5-HT3 agonists in humans are unknown.
  • RESULTS: MKC-733 (4 mg) increased the number of migrating motor complexes recorded in the antrum and duodenum (P < 0.001), but had no effect on post-prandial motility.
  • [MeSH-major] Gastrointestinal Motility / drug effects. Serotonin 5-HT3 Receptor Agonists. Serotonin Receptor Agonists / pharmacology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616171.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pyridines; 0 / Quinuclidines; 0 / Serotonin 5-HT3 Receptor Agonists; 0 / Serotonin Receptor Agonists; 1G26B32139 / Pumosetrag
  •  go-up   go-down


41. Ersoy O, Ersoy R, Yayar O, Demirci H, Tatlican S: H pylori infection in patients with Behcet's disease. World J Gastroenterol; 2007 Jun 7;13(21):2983-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A two-week triple therapy for H pylori eradication was administered to H pylori positive patients.
  • Two months after the treatment, the patients were evaluated by urea-breath test for eradication control.
  • The mean follow-up time was 35 +/- 14 mo (16-84 mo).
  • Aphthous or deep ulcer in esophagus, stomach and duodenum had never been confirmed by endoscopic examination.
  • Most gastric lesions were gastric erosion (40%) and the most duodenal lesions were duodenitis (17.5%) in two groups.
  • The two-week triple eradication therapy was successful in 75% of the patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Biopsy. Case-Control Studies. Clarithromycin / therapeutic use. Drug Therapy, Combination. Endoscopy, Gastrointestinal. Female. Helicobacter pylori / pathogenicity. Humans. Male. Metronidazole / therapeutic use. Middle Aged. Prevalence. Pyloric Antrum / microbiology. Pyloric Antrum / pathology. Tetracycline / therapeutic use

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589951.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; F8VB5M810T / Tetracycline; H1250JIK0A / Clarithromycin
  • [Other-IDs] NLM/ PMC4171153
  •  go-up   go-down


42. Bao C, Hu S, Zhou G, Tian Y, Wu Y, Sheng Z: Effect of carbachol on intestinal mucosal blood flow, activity of Na+-K+-ATPase, expression of aquaporin-1, and intestinal absorption rate during enteral resuscitation of burn shock in rats. J Burn Care Res; 2010 Jan-Feb;31(1):200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A catheter was inserted into the proximal duodenum (5 cm distal to pylorus) and distal ileum (5 cm proximal to cecum), of each rats through laparotomy, thus a segment of intestine was virtually isolated to form a loop for inlet and outlet of introduced fluid.
  • Then, animals were killed, and specimens of intestinal tissue were obtained for the determination of the activity of Na-K-ATPase, hematoxylin-eosin coloring, and expression of AQP-1.
  • [MeSH-major] Aquaporin 1 / metabolism. Burns / metabolism. Carbachol / pharmacology. Intestinal Absorption / drug effects. Intestinal Mucosa / drug effects. Shock, Traumatic / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism
  • [MeSH-minor] Animals. Cholinergic Agonists / pharmacokinetics. Enteral Nutrition. Fluid Therapy. Male. Rats. Rats, Wistar. Regional Blood Flow / drug effects

  • MedlinePlus Health Information. consumer health - Burns.
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061857.001).
  • [ISSN] 1559-0488
  • [Journal-full-title] Journal of burn care & research : official publication of the American Burn Association
  • [ISO-abbreviation] J Burn Care Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aqp1 protein, rat; 0 / Cholinergic Agonists; 146410-94-8 / Aquaporin 1; 8Y164V895Y / Carbachol; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


43. Madisch A, Wiedbrauck F, Marquard F, Stolte M, Hotz J: [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. Z Gastroenterol; 2002 Feb;40(2):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently.
  • CASE REPORTS: In 2 men and 4 women (age 49-78 years) with advanced colon (n = 2), gastric (n = 3 ) and gallbladder (n = 1) cancer a palliative weekly high-dose infusional 5-fluorouracil (2,6 g/m(2)/24 h) and folinic acid (500 mg/m(2)/2 h) chemotherapy was performed.
  • Few days after 1-5 chemotherapy courses the patients were admitted to our hospital with abdominal pain and partly severe watery diarrhea (up to 20 times evacuations/per day).
  • In 4 patients endoscopy of the upper GI-tract showed a severe inflammation (n = 1) and a fibrinopurulent exsudate, severe edema and isolated ulcerations (n = 3) of jejunum after gastrectomy or duodenum with intact stomach.
  • CONCLUSIONS: The present cases demonstrate that high-dose 5-fluorouracil-based chemotherapy not only induces a colitis but also may involve the upper small intestine tract.
  • Consequently, it represents an increasing and serious adverse event of high-dose chemotherapy.
  • The etiology of the enterocolitis (drug- or bacterial-induced) needs further investigations in order to find a causal therapy and/or prophylaxis.
  • [MeSH-major] Colitis / chemically induced. Colorectal Neoplasms / drug therapy. Fluorouracil / adverse effects. Gallbladder Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Endoscopy, Gastrointestinal. Enterocolitis, Necrotizing / chemically induced. Enterocolitis, Necrotizing / diagnosis. Enterocolitis, Necrotizing / pathology. Female. Follow-Up Studies. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastroenteritis / chemically induced. Gastroenteritis / diagnosis. Gastroenteritis / pathology. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Middle Aged. Palliative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11857099.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Nishizaki D, Takamatsu T, Iwasa Y: Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma. Hepatogastroenterology; 2008 May-Jun;55(84):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma.
  • Herein is described a mesenteric diffuse large B cell lymphoma (DLBCL) case with a bulky mass which had achieved a complete remission by the combination therapy of a surgical resection and the CHOP chemotherapy with rituximab.
  • A 78 year old man was referred to the Rakuwakai-Otowa Hospital due to a left lower abdominal tumor.
  • By the gastro-duodenoscopy, DLBCL of non-Hodgkin's lymphoma was proven at the 2nd portion of the duodenum.
  • After the operation, it was determined to be Stage IV DLBCL and the chemotherapy based on the R-CHOP regimen was performed.
  • During the chemotherapy, he was confirmed to have achieved a complete remission.
  • Stage IV mesenteric DLBCLs with extensive bulky masses are thought to be the indication for the combination therapy of surgical resection and multiagent chemotherapy with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Mesentery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Ileum / pathology. Ileum / surgery. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Staging. Prednisolone / administration & dosage. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705290.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


45. Oosting SF, Peters FT, Hospers GA, Mulder NH: A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. J Med Case Rep; 2010;4:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The condition is attributed to a responding malignant melanoma in the gastrointestinal tract.
  • A computed tomography scan showed massive ascites, lymphadenopathy and liver lesions suspect for metastases.
  • An upper gastrointestinal endoscopy was performed and revealed multiple dark lesions of 5 mm to 10 mm in his stomach and duodenum.When his skin was re-examined, an irregular pigmented lesion over the left clavicle measuring 15 mm x 8 mm with partial depigmentation was found.
  • Histological examination of a duodenal lesion was consistent with a diagnosis of metastatic melanoma.
  • The patient was started on systemic treatment with dacarbazine 800 mg/m2 every three weeks and he was discharged one day after the first dose.
  • A laparotomy was discussed with the patient and his family but he decided to go home with symptomatic treatment.
  • Gastrointestinal perforations due to responding tumors are a well-known complication of systemic treatment of gastrointestinal lymphomas.
  • However, as the response rate of metastatic melanoma to dacarbazine is only 10% to 20%, and responses are usually only partial, perforation due to treatment response in metastatic melanoma is rare.Medical oncologists should be aware of the risk of bowel perforation after starting cytotoxic chemotherapy on patients with gastrointestinal metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] J Pediatr Surg. 1999 Jul;34(7):1169-74 [10442615.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):145-56 [18077098.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001215 [10796759.001]
  • [Cites] Arch Surg. 1964 Jun;88:969-73 [14132002.001]
  • [Cites] Mayo Clin Proc. 2006 Apr;81(4):511-6 [16610571.001]
  • [Cites] J Pediatr Surg. 2007 Mar;42(3):E1-3 [17336175.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • (PMID = 20180962.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2829594
  •  go-up   go-down


46. Radu V, Ion D, Serban MB, Ciurea M: Locally aggressive colonic and rectal cancer--clinical trial. J Med Life; 2010 Jul-Sep;3(3):314-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally aggressive colonic and rectal cancer--clinical trial.
  • This clinical trial studies local invasions from primary colonic and rectal cancers (urinary bladder, abdominal wall, small bowls, uterus, vagina, stomach, bile tract, spleen, duodenum, pancreas, ureters, kidneys), with or without undiscovered metastasis.
  • Primary locally aggressive colonic and rectal cancers include tumors that are staged T4N1-2Mx on diagnosis, and are often associated with a lower prognosis than earlier cancers.
  • Diagnosis is based on thorough clinical evaluation, imagistic support: abdominal XR with contrast (barium enema), colonoscopy, abdominal and pelvic ultrasound exam, endoscopic endolumenal ultrasound exam, abdominal and pelvic CT/IRM with contrast (administrated both orally and intravenously), PET Scan, and intra-operatory confirmation.
  • Radical nuanced surgery is the base of treatment of the locally aggressive colon-rectal cancer.
  • The studies have shown that in certain localizations of the colon-rectal cancer, the locally aggressive forms can be better controlled by using multimodal therapy, including radiotherapy, either external or guided intraoperatory radiotherapy and chemotherapy with much better results.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 1997;48:191-202 [9046955.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):872-7 [19124803.001]
  • (PMID = 20945823.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019005
  •  go-up   go-down


47. Matsuzu K, Ike H, Cho H, Ashida A, Fujikawa H, Saito B, Hayashi T, Fujii K, Kojima Y, Narui K, Fujii Y, Makino T, Wada N, Rino Y, Masuda M: [Long survival of a case of unresected duodenal cancer treated by S-1 before and after duodenojejunostomy]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long survival of a case of unresected duodenal cancer treated by S-1 before and after duodenojejunostomy].
  • Detailed examination revealed a duodenal cancer of the ascending limbs.
  • Since she refused the resection, the administration of S-1 alone was commenced.
  • After one course of this treatment, oral intake became impossible.
  • Duodenography and endoscopy showed duodenal obstruction, and she underwent surgery.
  • The tumor proved to be unresectable due to direct invasion of the inferior vena cava.
  • The combination of S-1 administration and bypass operation provides a useful alternative for the treatment of unresectable duodenal cancer with stenosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Duodenal Neoplasms / therapy. Duodenostomy. Jejunostomy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Drug Combinations. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755837.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


48. Kim SI, Park YH, Choi SJ, Ryoo BY, Lee SS, Son HB, Suh YA, Kim DH, Kim SH, Choi KS, Kweon YJ: A Case of Extraskeletal Ewing's Sarcoma Arising from Duodenum. Cancer Res Treat; 2002 Dec;34(6):461-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Extraskeletal Ewing's Sarcoma Arising from Duodenum.
  • Recently, Ewing's sarcoma of the bone, primitive neuroectodermal tumor (PNET), Askin tumor and EES have been included into the family of Ewing's tumors, due to the overlapping features relating to their clinico-pathological and cytogenetic appearance.
  • We experienced a case of an EES arising from the duodenum in a 14-year-old girl who presented with hematemesis and epigastric discomfort.
  • A duodenal biopsy specimen revealed the infiltration of small round cells and rich vasculatures, with immunohistochemical finding of MIC-2 (CD99) (+), vimentin (+), CD56 (NCAM) (+), LCA (-), T-cell (-), B-cell (-), CD43 (-) and CD68 (-).
  • She was treated with several cycles of multiagent chemotherapy, and achieved an initial partial response, but rapid progression of tumor followed, so she was treated with surgical excision.
  • This is the first case report of an EES arising from the duodenum in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26680906.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


49. Cherniavskaia GM, Belodorobova EI, Plekhanova EV, Pozdniakov RA, Pleshko RI: [Impact of long-term systemic glucocorticoid therapy for bronchial asthma on the occurrence and course of peptic ulcer]. Klin Med (Mosk); 2003;81(2):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of long-term systemic glucocorticoid therapy for bronchial asthma on the occurrence and course of peptic ulcer].
  • The study was undertaken to examine the incidence and specific features of peptic ulcer (PU) of the gastroduodenal area (GDA) in bronchial asthma (BA) and the impact of long-term oral maintenance therapy with systemic glucocorticosteroids (GCS) on the occurrence and course of peptic ulcer.
  • The commonest site of an ulcerative process in the duodenum (90%) and its frequent combination with reflux esophagitis (84.1%) are noteworthy, which is likely to import some specific features to the clinical picture of GDA PU in BA.
  • The clinical and endoscopic features of the course of PU in patients with comorbidity were analyzed in relation to the use of GCS therapy.
  • The analysis revealed that the incidence of PU did not depend on the severity and type of BA and on the use of GCS therapy.
  • There was no significant negative impact of long-term small-dose GCS therapy on the clinical and endoscopic picture of PU in BA.
  • The findings suggest that in BA, favorable conditions arose for realizing the predisposition to PU, which makes it necessary to carry out further studies to reveal the possible mechanisms that are responsible for the formation of concomitant diseases; this may be of fundamental importance in developing pathogenetically substantiated therapy for the above category of patients.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / adverse effects. Asthma / drug therapy. Glucocorticoids / administration & dosage. Glucocorticoids / adverse effects. Peptic Ulcer / chemically induced
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Dyspepsia / etiology. Endoscopy, Digestive System. Esophagitis, Peptic / etiology. Female. Humans. Male. Middle Aged. Steroids. Time Factors

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12685234.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 0 / Steroids
  •  go-up   go-down


50. La Vecchia C, Tavani A: A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs. Eur J Cancer Prev; 2002 Apr;11(2):117-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs.
  • H2-receptor antagonists have been widely used since the late 1970s for the treatment of gastrointestinal ulcers and other benign conditions of the stomach, oesophagus and duodenum.
  • Several case reports suggested that long-term therapy with H2-receptor antagonists, mainly cimetidine and ranitidine, might increase the risk of gastric cancer.
  • After early case reports, at least six analytical epidemiological studies (two cohort and four case-control) were published, including a total of about 1000 cases of gastric cancer.
  • Some excess risk was still apparent during the first 5 years of drug use, probably due to incorrect diagnosis and treatment of pre-existing neoplastic gastric lesions, but the estimated RR was not above unity for > or = 10 years since starting drug treatment in the two studies including information on long-term use.
  • The findings of analytical epidemiological studies are thus consistent with the absence of a causal association between H2-receptor antagonist use and gastric cancer risk.
  • Data on oesophageal and colorectal cancer do not support a relevant relation between cimetidine use and the risk of these neoplasms.
  • With reference to total cancer mortality, in a Danish cohort study, for males the RR was 1.9 in the first year, and 1.4 in the first 5 years; corresponding values for females were 1.7 and 1.5.
  • The excess risk in the first year was essentially due to gastric cancer.
  • [MeSH-major] Cimetidine / adverse effects. Histamine H2 Antagonists / adverse effects. Peptic Ulcer / drug therapy. Stomach Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIMETIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11984128.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 80061L1WGD / Cimetidine
  • [Number-of-references] 51
  •  go-up   go-down


51. Xu JF, Qiu SJ, Song YD, Han LJ: [Value of multi-slice spiral CT in the diagnosis and therapeutic effect evaluation of gastrointestinal stromal tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr;30(4):875-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of multi-slice spiral CT in the diagnosis and therapeutic effect evaluation of gastrointestinal stromal tumors].
  • OBJECTIVE: To analyze the CT manifestations of gastrointestinal stromal tumors, and explore the value of CT in the diagnosis and therapeutic effect evaluation of these tumors.
  • RESULTS: Of the 39 patients with gastrointestinal stromal tumors, 2 had esophageal stromal tumors, 23 had gastric stromal tumor, 7 had duodenal stromal tumor, 4 had jejunal stromal tumors, 2 had ileal stromal tumors, and 1 had colon stromal tumor.
  • Twenty-five patients were found to have highly malignant tumors, and 11 had low-grade tumors, with the other 3 having tumors of unidentifiable nature.
  • Of the 27 cases with a tumor diameter over 5 cm, 23 had malignant stromal tumors, and the tumor mass showed heterogeneous density with central necrosis and cystic and the solid portion of the tumor exhibited mild to moderate enhancement.
  • Six patients were found to have intratumoral punctate calcification, and 17 with malignant tumors showed high peripheral enhancement, with the solid portion of the tumors showing delayed enhancement.
  • The 6 patients with unresectable tumors received chemotherapy resulting in significantly reduced tumor diameter and cystic and necrotic foci in the tumor.
  • CONCLUSION: Multi-slice spiral CT allows precise localization and qualitative assessment of gastrointestinal stromal tumors, and also helps in the evaluation of the therapeutic effect.
  • [MeSH-major] Duodenal Neoplasms / radiography. Gastrointestinal Stromal Tumors / radiography. Stomach Neoplasms / radiography. Tomography, Spiral Computed


52. Schütte K, Bornschein J, Kuester D, Wieners G, Malfertheiner P: [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head]. Med Klin (Munich); 2010 Apr;105(4):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head].
  • The reason was an arterial hemorrhage from a duodenal tumor that could only be stopped by an angiographic intervention.
  • In the further staging, there was evidence for a neuroendocrine carcinoma of the pancreatic head with infiltration of the duodenum and hepatic metastases.
  • After recurrent bleeding with arrosion of a branch of the superior mesenteric artery, a duodenum-preserving pancreatic head resection was performed.
  • Afterwards, the systemic therapy was changed to a palliative chemotherapy with streptozotocin and 5-fluorouracil due to local progression of the disease and a Ki-67 index of 4% in the primary tumor.
  • The therapy depends on the local spread and histological grading as well as symptoms of the patient.
  • However, even in a palliative situation, there can be benefit for the patient in case of a tumor mass reduction of > 90%.
  • Alternative therapies in the palliative situation are somatostatin analogs, a classic systemic chemotherapy, or locoregional interventional procedures.
  • [MeSH-major] Duodenum / pathology. Gastrointestinal Hemorrhage / etiology. Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Endoscopy, Digestive System. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):221-32 [17639039.001]
  • [Cites] J Clin Gastroenterol. 2006 Aug;40(7):572-82 [16917396.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • (PMID = 20455052.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Venkatasubramani N, Rudolph CD, Sood MR: Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. BMC Gastroenterol; 2008;8:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erythromycin, a non-peptide motilin receptor agonist, induces phase 3 of the migrating motor complex (MMC) in the antro-duodenum and also reduces oro-cecal transit time.
  • RESULTS: The mean (SE of mean) AUC in the colon during the fasting, post-erythromycin and postprandial phases of the study was 2.1 mmHg/sec (0.35), 0.99 mmHg/sec (0.17) and 3.05 mmHg/sec (0.70) respectively.
  • [MeSH-major] Colon / drug effects. Colon / physiopathology. Erythromycin / pharmacology. Gastrointestinal Agents / pharmacology. Gastrointestinal Diseases / physiopathology. Gastrointestinal Motility / drug effects
  • [MeSH-minor] Child. Child, Preschool. Constipation / drug therapy. Constipation / physiopathology. Dose-Response Relationship, Drug. Fecal Incontinence / drug therapy. Fecal Incontinence / physiopathology. Female. Humans. Male. Manometry. Muscle Contraction / drug effects. Muscle Contraction / physiology. Muscle, Smooth / drug effects. Muscle, Smooth / physiology. Peristalsis / drug effects. Peristalsis / physiology. Receptors, Gastrointestinal Hormone / agonists. Receptors, Neuropeptide / agonists. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurogastroenterol Motil. 2001 Feb;13(1):27-35 [11169123.001]
  • [Cites] Ann Pharmacother. 2005 Apr;39(4):706-11 [15755792.001]
  • [Cites] Aliment Pharmacol Ther. 2001 May;15(5):595-603 [11328252.001]
  • [Cites] Early Hum Dev. 2001 Dec;65(2):91-6 [11641030.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Jan;34(1):13-5 [11753157.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Jan;34(1):23-5 [11753159.001]
  • [Cites] Am J Surg. 2002 Apr;183(4):413-8 [11975929.001]
  • [Cites] Neurogastroenterol Motil. 2002 Aug;14(4):411-20 [12213110.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):357-63 [12891536.001]
  • [Cites] Gastroenterology. 1972 Mar;62(3):401-4 [5011531.001]
  • [Cites] Pediatrics. 1975 Sep;56(3):412-6 [1161398.001]
  • [Cites] Dig Dis Sci. 1979 Jul;24(7):497-500 [456236.001]
  • [Cites] Eur J Clin Invest. 2000 Jan;30(1):66-71 [10620004.001]
  • [Cites] Peptides. 2000 Feb;21(2):283-7 [10764957.001]
  • [Cites] Clin Pediatr (Phila). 2000 Oct;39(10):603-7 [11063041.001]
  • [Cites] Gastroenterology. 1980 Oct;79(4):716-9 [7409389.001]
  • [Cites] Scand J Gastroenterol. 1987 Sep;22(7):781-4 [3672037.001]
  • [Cites] J Pediatr. 1992 May;120(5):690-5 [1578302.001]
  • [Cites] Aliment Pharmacol Ther. 1992 Oct;6(5):589-95 [1420750.001]
  • [Cites] Dig Dis Sci. 1994 Jul;39(7):1399-404 [8026249.001]
  • [Cites] J Pediatr. 1995 Oct;127(4):593-6 [7562282.001]
  • [Cites] Dig Dis Sci. 1995 Nov;40(11):2446-9 [7587829.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 Apr;24(4):411-8 [9144124.001]
  • [Cites] Neurogastroenterol Motil. 1997 Sep;9(3):143-50 [9347469.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):209-13 [9577904.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1998 Oct;27(4):398-402 [9779966.001]
  • [Cites] Gut. 1998 Sep;43(3):395-400 [9863486.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2001 May;84(3):F177-82 [11320044.001]
  • (PMID = 18718006.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; 0 / Receptors, Gastrointestinal Hormone; 0 / Receptors, Neuropeptide; 0 / motilin receptor; 33H58I7GLQ / erythromycin lactobionate; 63937KV33D / Erythromycin
  • [Other-IDs] NLM/ PMC2529327
  •  go-up   go-down


54. Carvajal H C, Iturra U S, Justiniano P JC, Bustamante Z M, Contreras P JE, Lombardi S J, Capetillo Fuentes M: [Duodenal gastrointestinal stromal tumors. Report of a case]. Rev Med Chil; 2006 Apr;134(4):481-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Duodenal gastrointestinal stromal tumors. Report of a case].
  • Gastrointestinal stromal tumors (GIST) are lesions whose diagnosis and treatment have varied in the last decade.
  • A duodenography showed an elevated lesion in the third portion of the duodenum with a central ulceration.
  • It was initially managed with tumorectomy and primary closure of the duodenum.
  • The pathological study of the surgical specimen revealed a low grade gastrointestinal stromal tumor.
  • Three years later, the tumor recurred and pancreatoduodenectomy was performed.
  • Due to the high risk of malignant potential, tumor size, number of mitoses and the presence of necrosis, imatinib mesylate was started.
  • [MeSH-major] Duodenal Neoplasms. Gastrointestinal Stromal Tumors
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Benzamides. Duodenal Ulcer / drug therapy. Duodenal Ulcer / radiography. Duodenal Ulcer / surgery. Gastrointestinal Hemorrhage / drug therapy. Gastrointestinal Hemorrhage / radiography. Gastrointestinal Hemorrhage / surgery. Humans. Imatinib Mesylate. Male. Pancreaticoduodenectomy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit. Pyrimidines / therapeutic use. Recurrence

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758085.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


55. Lee S, Kim SK, Lee DY, Park K, Kumar TS, Chae SY, Byun Y: Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone. J Pharm Sci; 2005 Nov;94(11):2541-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A great number of currently available drugs and those being developed that fall under the class III of the BCS (biopharmaceutical classification system) possess high therapeutic potential but cannot be delivered by peroral absorption.
  • In this study, we synthesized a cationic analog of deoxycholic acid and evaluated its efficacy as a potential oral drug carrier for anionic BCS class III drugs using ceftriaxone as a model drug.
  • These drug complexes were formulated with propylene glycol and their oral bioavailabilities were evaluated.
  • When the ceftriaxone/DCEA formulation was administered into a nonclosed segment of duodenum of rats, C(max) (the maximum drug concentration in plasma) and AUC (area under the curve) were significantly increased and its bioavailability was increased up to 70%.
  • Therefore, the new cationic carriers proposed in this study could improve the absorption of BCS class III drugs in the intestine with maintaining their full biological activity.
  • [MeSH-major] Anti-Bacterial Agents / pharmacokinetics. Ceftriaxone / pharmacokinetics. Deoxycholic Acid / analogs & derivatives. Drug Carriers
  • [MeSH-minor] Animals. Area Under Curve. Biological Availability. Biopharmaceutics. Cations. Duodenum / metabolism. Half-Life. Intestinal Absorption. Male. Metabolic Clearance Rate. Propylene Glycol / chemistry. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Propylene glycol .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200559.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cations; 0 / Drug Carriers; 0 / N-deoxychoylethylenediamine; 005990WHZZ / Deoxycholic Acid; 6DC9Q167V3 / Propylene Glycol; 75J73V1629 / Ceftriaxone
  •  go-up   go-down


56. Mahajan SK, Vaidya P, Sood BR, Gupta D, Sharma A: Duodenal diverticular haemorrhage in a patient taking NSAID. J Assoc Physicians India; 2003 Apr;51:416-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal diverticular haemorrhage in a patient taking NSAID.
  • Upper gastrointestinal (UGI) barium series with small bowel follow through revealed a diverticulum on medial wall of second part of duodenum and there was evidence of ulcer in diverticulum.
  • [MeSH-major] Diclofenac / adverse effects. Diverticulum / chemically induced. Duodenal Diseases / chemically induced. Gastrointestinal Hemorrhage / chemically induced
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Fluoroscopy. Humans. Low Back Pain / drug therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12723664.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


57. Valldeoriola F, Cámara A: [Intraduodenal infusion of levodopa]. Rev Neurol; 2010 Jul 1;51(1):41-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Infusión intraduodenal de levodopa.
  • In the advanced stages of Parkinson's disease (PD), the conventional orally-administered pharmacological treatment can prove to be insufficient to control the motor complications associated with the disease.
  • One of the causes involved in the genesis of the motor fluctuations that are observed in PD is the variable absorption of the medication due to an irregular or erratic emptying of the gastric content.
  • Today, a method of therapy is now available that allows levodopa to be administered directly into the duodenum at a continuous rate by a perfusor.
  • The medication is applied through a duodenal catheter implanted by means of a percutaneous endoscopic gastrostomy.
  • Duodopa has proved to be effective in reducing the percentage of off time and in diminishing the periods with disabling dyskinesias.
  • This therapy has also proved to be useful for relieving certain non-motor aspects associated with PD and presents fewer limitations regarding indication for advanced PD patients than those that usually exist for the case of deep brain stimulation.
  • Although the therapy has proved to be effective, it is not free of complications arising from malfunctioning of the infusion system or in relation to the percutaneous endoscopic gastrostomy.
  • [MeSH-major] Dopamine Agents. Duodenum / drug effects. Levodopa. Parkinson Disease / drug therapy
  • [MeSH-minor] Carbidopa / therapeutic use. Deep Brain Stimulation. Drug Administration Routes. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568067.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Dopamine Agents; 46627O600J / Levodopa; MNX7R8C5VO / Carbidopa
  • [Number-of-references] 34
  •  go-up   go-down


58. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T: Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol; 2010 Apr;45(4):370-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the duodenum and terminal ileum are considered to be the most common sites of origin, the development of wireless capsule endoscopy and double-balloon enteroscopy has increased the detection of GI-FL in every part of the small intestine.
  • If the lymphoma causes no symptoms, immediate treatment may not be necessary.
  • Standard therapy has not yet been established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a combination of these therapies, is sometimes performed based on the therapeutic regimens for nodal FL.
  • Regimens including conventional chemotherapy with rituximab, which achieve high response rates in nodal FL, are commonly used for GI-FL.
  • The results of a few series on the long-term outcomes of patients with GI-FL treated with conventional therapy indicate a median relapse-free time ranging from 31 to 45 months.
  • On the other hand, in patients with GI-FL who were followed without treatment, the median time to disease progression was 37.5 months.
  • Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision.
  • Ongoing research on biomarkers to guide individualized GI-FL therapy may provide invaluable information that will lead to the establishment of a standard therapeutic regimen.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / therapy. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Kyoto University Research Information Repository - Articles. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 May;128(6):1579-605 [15887153.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):113-9 [16648662.001]
  • [Cites] Blood. 2000 Feb 1;95(3):783-9 [10648386.001]
  • [Cites] Ann Oncol. 2006 May;17 (5):780-4 [16497824.001]
  • [Cites] Leukemia. 1993 Feb;7(2):268-73 [8426481.001]
  • [Cites] Dig Dis Sci. 2001 Mar;46(3):567-70 [11318534.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1031-5 [17353993.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):432-9 [11295923.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Intern Med. 2007;46(3):141-2 [17268132.001]
  • [Cites] Recent Results Cancer Res. 2000;156:116-24 [10802871.001]
  • [Cites] J Mol Diagn. 2007 Sep;9(4):530-7 [17652637.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Hepatogastroenterology. 2007 Sep;54(78):1658-61 [18019688.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):105-13 [12507894.001]
  • [Cites] J Clin Pathol. 2008 Mar;61(3):377-81 [17601964.001]
  • [Cites] J Clin Gastroenterol. 2008 Oct;42(9):997-1002 [18719510.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):763-5 [18207144.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1563-9 [10995001.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):408-10 [12902896.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Can J Gastroenterol. 1997 Jan-Feb;11(1):31-4 [9113795.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):735-44 [11298531.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):17-29 [9443038.001]
  • [Cites] Mod Pathol. 2000 May;13(5):586-90 [10824932.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] Endoscopy. 2009 Feb;41(2):175-8 [19214900.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):442-52 [8604811.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):772-84 [15352980.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Aug;5(8):e30 [17625984.001]
  • [Cites] Histopathology. 1998 Feb;32(2):116-25 [9543667.001]
  • [Cites] Ann Hematol. 2004 May;83(5):276-8 [15060746.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):213-6 [11793448.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Ann Hematol. 2002 Apr;81(4):228-31 [11976827.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv48-50 [12746269.001]
  • [Cites] Haematologica. 1992 Mar-Apr;77(2):156-61 [1398301.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1083-100 [15488559.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):92-6 [11427853.001]
  • [Cites] Springer Semin Immunopathol. 1990;12(2-3):239-50 [2205943.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):940-9 [19396151.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Nov;5(11):A24 [17981239.001]
  • [Cites] Intern Med. 2007;46(11):705-9 [17541220.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):652-9 [17582800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):175-83 [16721817.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Acta Oncol. 2001;40(2-3):213-23 [11441933.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] J Clin Gastroenterol. 2002 Feb;34(2):155-9 [11782611.001]
  • [Cites] Clin Transl Oncol. 2007 Jul;9(7):471-2 [17652063.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1035-8 [15335250.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):218-24 [8426197.001]
  • [Cites] Hum Pathol. 1999 May;30(5):581-7 [10333231.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Gastrointest Endosc. 2009 Jan;69(1):158-9; discussion 159 [19111697.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Endoscopy. 2010 Jan;42(1):86; author reply 87 [20066597.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1556; author reply 1556-7 [14628813.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • [Cites] Blood. 1986 Oct;68(4):837-45 [3530348.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):315-20 [3014037.001]
  • [Cites] Intern Med. 2006;45(5):309-11 [16596000.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathol Res Pract. 2007;203(9):691-4 [17643847.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):547-52 [18687756.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):363-72 [6869665.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):285-6 [12192212.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E39 [17285511.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1046-51 [9831200.001]
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] World J Gastroenterol. 2004 Sep 1;10(17):2602-4 [15300917.001]
  • [Cites] J Gastroenterol. 2003;38(6):584-7 [12856675.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):743-8 [11251169.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Intern Med. 2008;47(13):1277-8 [18591856.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1852-6 [12200703.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] J Gastroenterol. 2003;38(5):512-3 [12768397.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2499-505 [10561315.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • (PMID = 20084529.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 126
  •  go-up   go-down


59. Sivasubramaniam SD, Finch CC, Rodriguez MJ, Mahy N, Billett EE: A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues. Cell Tissue Res; 2003 Sep;313(3):291-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues.
  • The distributions of monoamine oxidase (MAO)-A and -B proteins and mRNAs in human heart, lung, liver, duodenum, kidney and vasculature were compared using immunohistochemistry and cRNA in situ hybridisation.
  • MAO-A and -B mRNA were detected in all tissues, to differing extents, but particularly in glomeruli, hepatocytes, and the crypts, muscularis mucosa and muscularis externa of duodenum.
  • Renal proximal and distal tubules and loops of Henle had more intense labelling for mRNA of MAO-B than MAO-A; this was reflected in MAO protein expression.
  • Both isoforms were expressed equally in duodenal villi, crypts, muscularis externa and mucosa; lower level expression occurred in mucosal and submucosal cells.
  • The data reveal widespread tissue distribution of MAO mRNAs and proteins, but indicate that presence of MAO mRNAs does not invariably reflect quantitatively its protein expression.
  • [MeSH-minor] Aged. Aged, 80 and over. Blood Vessels / cytology. Blood Vessels / enzymology. Blood Vessels / metabolism. Duodenum / cytology. Duodenum / enzymology. Duodenum / metabolism. Female. Hepatocytes / enzymology. Hepatocytes / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Isoenzymes / genetics. Isoenzymes / metabolism. Kidney / blood supply. Kidney / enzymology. Kidney / metabolism. Liver / cytology. Liver / enzymology. Liver / metabolism. Lung / cytology. Lung / enzymology. Lung / metabolism. Male. Myocardium / cytology. Myocardium / enzymology. Myocardium / metabolism. Renal Artery / enzymology. Renal Artery / metabolism. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898212.001).
  • [ISSN] 0302-766X
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Proteins; 0 / RNA, Messenger; EC 1.4.3.4 / Monoamine Oxidase
  •  go-up   go-down


60. Sheikh RA, Prindiville TP, Yenamandra S, Munn RJ, Ruebner BH: Microsporidial AIDS cholangiopathy due to Encephalitozoon intestinalis: case report and review. Am J Gastroenterol; 2000 Sep;95(9):2364-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No organisms were identified on routine light microscopy of the biopsy specimens from the duodenum, ampulla, and bile duct. E. intestinalis spores were demonstrated in the bile duct biopsies, by methylene blue and azure 11 staining and confirmed by electron microscopy.
  • Albendazole therapy was successful in eradicating E. intestinalis with clinical improvement and improvement in CD4 count.
  • Albendazole therapy was delayed and may have been too late to prevent bile duct damage; the drug had to be approved by the US Food and Drug Administration for compassionate use.
  • [MeSH-minor] Adult. Albendazole / therapeutic use. Animals. Antiprotozoal Agents / therapeutic use. Bile Ducts / parasitology. Bile Ducts / ultrastructure. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11007244.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiprotozoal Agents; F4216019LN / Albendazole
  • [Number-of-references] 46
  •  go-up   go-down


61. Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA: Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol; 2007 Dec;58 Suppl 6:23-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review focuses on the role of melatonin in upper portion of gastrointestinal tract (GIT), including oral cavity, esophagus, stomach and duodenum, where this indole is generated and released into the GIT lumen and into the portal circulation to be uptaken, metabolized by liver and released with bile into the duodenum.
  • Melatonin in GIT was shown to be generated in about 500 times larger amounts than it is produced in pineal gland.
  • The production of melatonin by pineal gland shows circadian rhythm with high night-time peak, especially at younger age, followed by the fall during the day-light time.
  • Following pinealectomy, the light/dark cycle of plasma melatonin levels disappears, while its day-time blood concentrations are attenuated but sustained mainly due to its release from the GIT.
  • [MeSH-minor] Acetylserotonin O-Methyltransferase / metabolism. Animals. Arylalkylamine N-Acetyltransferase / metabolism. Eating / physiology. Gastrointestinal Diseases / drug therapy. Gastrointestinal Diseases / metabolism. Gastrointestinal Diseases / physiopathology. Humans. Intestinal Mucosa / metabolism. Liver / physiology. Mouth Diseases / drug therapy. Mouth Diseases / metabolism. Mouth Diseases / physiopathology. Pineal Gland / enzymology. Pineal Gland / physiology. Pineal Gland / secretion. Tryptophan / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • Hazardous Substances Data Bank. MELATONIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212399.001).
  • [ISSN] 0867-5910
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 8DUH1N11BX / Tryptophan; EC 2.1.1.4 / Acetylserotonin O-Methyltransferase; EC 2.3.1.87 / Arylalkylamine N-Acetyltransferase; JL5DK93RCL / Melatonin
  • [Number-of-references] 68
  •  go-up   go-down


62. Sun JJ, Wu ZY: [Treatment of 54 cases of primary malignant duodenal tumor]. Zhonghua Wai Ke Za Zhi; 2004 Mar 7;42(5):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of 54 cases of primary malignant duodenal tumor].
  • OBJECTIVE: To study the treatment of primary malignant duodenal tumor.
  • METHOD: The data of 54 cases of primary malignant duodenal tumor during 1993 approximately 2003 were analyzed retrospectively.
  • Correct diagnosis rates of image examination were endoscopic retrograde cholangiopancreatography 92.8%, air barium double radiography 70.8%, gastroscopy 50.0%, CT 21.9%, MRI 21.4%.
  • Tumor location was 1 in duodenal bulb, 45 in descending portion, 3 in horizontal part and none in ascending portion.
  • 48 malignant tumors were operated, 31 pancreaticoduodenectomy, 1 pancreaticoduodenectomy and partial resection of superior mesenteric vein, 6 radical segmental duodenal resection, 1 palliative segmental duodenal resection, 3 duodenal wedge resection, 5 bypass operation (gastrojejunostomy and/or cholangiojejunostomy), 1 jejunostomy.
  • Adjuvant chemotherapy was given in 13 cases.
  • Median survival months were 24, 10, 38 and 16 respectively for radical operation group, palliative operation group, with postoperative adjuvant therapy group and without postoperative adjuvant therapy group.
  • No significant survival time was found between radical operation group and palliative operation group, adjuvant therapy group and without postoperative adjuvant therapy group, pancreaticoduodenectomy group and radical segmental duodenal resection group in statistics.
  • Among lymphyaden metastasis, tumor size, tumor depth, tumor thrombi, pathologic type and operative methods, only tumor thrombi had prognostic significance in multivariate analysis.
  • CONCLUSIONS: Pancreaticoduodenectomy and radical segmental duodenal resection should be selected for primary malignant duodenal tumor.
  • Postoperative adjuvant treatment is advocated.
  • [MeSH-major] Duodenal Neoplasms / surgery. Duodenostomy / methods. Pancreatectomy / methods
  • [MeSH-minor] Abdominal Pain / etiology. Adenocarcinoma / complications. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Duodenal Obstruction / etiology. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / etiology. Humans. Male. Middle Aged. Postoperative Care. Retrospective Studies. Surgical Wound Infection. Survival Analysis

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062015.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Woo KH, Kim JH, Yoon SB, Jang JH, Lee DH, Hong SH, Baek IH: Duodenal mucosa-associated lymphoid tissue lymphoma: a case report. Korean J Intern Med; 2007 Dec;22(4):296-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal mucosa-associated lymphoid tissue lymphoma: a case report.
  • Primary duodenal mucosa associated lymphoid tissue (MALT) lymphoma is very rare, and little is known about its clinical course or effective treatment.
  • We describe a case of primary duodenal MALT lymphoma that was resistant to Helicobacter pylon (H. pylori) eradication and regressed after chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP).
  • Gastroduodenoscopy revealed an irregular mucosal nodular lesion with ulceration extending from the bulb to the second portion of the duodenum.
  • We administered systemic CVP chemotherapy every 3 weeks.
  • [MeSH-major] Duodenum / pathology. Lymphoma, B-Cell, Marginal Zone / pathology

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):536-9 [10685764.001]
  • [Cites] J Clin Gastroenterol. 2000 Sep;31(2):169-71 [10993438.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):732-5 [15143903.001]
  • [Cites] Strahlentherapie. 1977 Apr;153(4):218-21 [857349.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):895-8 [6547634.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Scand J Gastroenterol. 2006 Mar;41(3):365-9 [16497629.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1674-8 [8942749.001]
  • [Cites] Lancet. 1997 Jan 4;349(9044):31-2 [8988128.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):214-6 [9508528.001]
  • [Cites] Scand J Gastroenterol. 1999 Feb;34(2):215-8 [10192204.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • (PMID = 18309692.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2687664
  •  go-up   go-down


64. Glória Silva F, Paiva M, Tavares A, Lacerda A, Pereira G, Marques A, Barata D, Cabral J: [Paediatric Burkitt lymphoma presenting as acute pancreatitis]. Acta Med Port; 2008 Sep-Oct;21(5):515-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Pancreatite aguda como manifestação de linfoma de Burkitt em idade pediátrica.
  • We present the case of a 13-year-old boy who was admitted to our Intensive Care Unit with the diagnosis of acute pancreatitis, bilateral pleural effusion and ascites.
  • Serial sonographic and computed tomography evaluations were suggestive of an infiltrative process of the gastric wall.
  • Endoscopy showed an infiltrative tumor of the gastric mucosa and duodenum with a giant ulcer.
  • After staging (stage III), the patient was treated according to FAB LMB 96 chemotherapy protocol, achieving complete remission.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187696.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


65. Spencer JA, Crosse BA, Mannion RA, Sen KK, Perren TJ, Chapman AH: Gastroduodenal obstruction from ovarian cancer: imaging features and clinical outcome. Clin Radiol; 2000 Apr;55(4):264-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroduodenal obstruction from ovarian cancer: imaging features and clinical outcome.
  • OBJECTIVE: The purpose of this study was to describe the imaging features and clinical significance of gastroduodenal obstruction from ovarian cancer.
  • MATERIALS AND METHODS: Eleven women with symptomatic gastroduodenal obstruction were identified over a 3-year period of prospective clinicoradiological review of cases managed in a specialist gynaecological oncology unit, during which period 438 women with ovarian cancer were managed.
  • Disease stages of these women at initial diagnosis were: stage II (four women), stage III (six), stage IV (one).
  • Symptomatic gastroduodenal relapse occurred at 9-103 months after initial diagnosis (median 20 months).
  • There were five cases of predominant involvement of the gastric body and six of the gastric outlet and duodenum.
  • In six cases, focal mass disease resulted in obstruction, in two cases there was diffuse gastric invasion, and in three cases encysted malignant ascites in the lesser sac caused gastric compression/obstruction - the 'squashed stomach syndrome'.
  • Diagnosis of obstruction was with CT in 10 of 11 cases.
  • Palliative interventional procedures relieved symptoms in these three cases, surgery was performed in three cases and the remainder were treated with chemotherapy and other palliative measures.
  • CONCLUSIONS: Gastroduodenal obstruction is rare in women with ovarian cancer.
  • [MeSH-major] Duodenal Obstruction / etiology. Gastric Outlet Obstruction / etiology. Ovarian Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Ascites / complications. Ascites / radiography. Female. Follow-Up Studies. Humans. Middle Aged. Prospective Studies. Stomach Neoplasms / secondary. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767185.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


66. Kamilova AT, Pazylova SA, Abdullaeva DA, Abduzhbarova ZM: [Efficacy of omeprazole in the treatment of Helicobacter pylori-associated duodenal ulcers... in children]. Lik Sprava; 2003 Dec;(8):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of omeprazole in the treatment of Helicobacter pylori-associated duodenal ulcers... in children].
  • We have observed 25 children: 15 (60%) girls, 10 (40%) boys in age of 11 to 15 y.o. with duodenum ulcer disease.
  • Omeprazolum was prescribed in doses: 20 mg 2 times per day over 7 days, after it 20 mg 1 time per day over 1 week.
  • The above-mentioned therapy showed good results, ulcer craters have been epithelized in more than a half of the children, in 68% of patients over 14 days.
  • Using of this therapy positively affects the inflammatory and structural changes of gastric mucous coat and the acid level.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965011.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Ulcer Agents; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin
  •  go-up   go-down


67. Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR: Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol; 2006 May;3(5):281-4; quiz 285
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum.
  • DIAGNOSIS: Duodenal neuroendocrine neoplasm showing gastrin expression and stage III (T3N2M0), poorly differentiated adenocarcinoma of the cecum arising from hyperplastic polyposis.
  • MANAGEMENT: Right-sided hemicolectomy with ileocolonic anastomosis, duodenal resection, leucovorin and 5-fluorouracil chemotherapy, annual colonoscopic surveillance, and polypectomy.
  • [MeSH-major] Adenocarcinoma. Colonic Neoplasms. Colonic Polyps. Duodenal Neoplasms. Gastrinoma. Neoplasms, Multiple Primary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Diagnosis, Differential. Female. Humans. Hyperplasia. Middle Aged. Treatment Outcome. Zollinger-Ellison Syndrome / diagnosis

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683006.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Kondo N, Furuya H, Yamamoto S, Nakano A, Sakashita Y: Diffuse large B-cell lymphoma in the ampulla of vater causing obstructive jaundice: report of a case. Surg Today; 2008;38(1):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Duodenal endoscopy revealed a mass in the ampulla of Vater and narrowing of the second portion of the duodenum, although diagnosing DLBCL from an endoscopic biopsy was impossible because there were several kinds of leukocytes in the infiltrate.
  • We performed pylorus-preserving pancreatoduodenectomy to establish a histological diagnosis, relieve the obstructive jaundice, and remove the narrowed second portion of the duodenum.
  • Histological and immunohistochemical examination of the surgically resected specimen confirmed a diagnosis of DLBCL.
  • Chemotherapy is the mainstay of treatment for DLBCL; however, surgery still plays an important role when the histological diagnosis cannot be established preoperatively and when complications are not amenable to nonsurgical therapy.
  • [MeSH-minor] Aged. Cholangiography. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Pancreaticoduodenectomy / methods

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Jun;5(6):969-81 [3295131.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2083-6 [7512441.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3083-8 [12115338.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):484-8 [9130997.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] J Comput Tomogr. 1986 Jan;10 (1):89-92 [3943363.001]
  • [Cites] South Med J. 1995 May;88(5):583-5 [7732453.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3186-9 [11721770.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1543-6 [9317083.001]
  • (PMID = 18085371.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Bobkov OV: [Cytobiochemical blood indices in patients with bleeding erosions and different methodical approach to their treatment]. Lik Sprava; 2004 Jul-Sep;(5-6):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytobiochemical blood indices in patients with bleeding erosions and different methodical approach to their treatment].
  • Two groups of patients with gastric and duodenum bleeding erosions have been treated with tradition approach (endoscopic and drug therapy) and local ozonotherapy (as for obtaining endoscopic homeostasis, so for further monotherapy).
  • Endoscopic monitoring, determination of intracellular glycogen, cell metabolic characteristic and lipid peroxidation study were used to control the efficacy of the treatment and course of the disease.

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Ozone.
  • Hazardous Substances Data Bank. OZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605818.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Hemostatics; 0 / Lipid Peroxides; 66H7ZZK23N / Ozone
  •  go-up   go-down


70. Katsinelos P, Kountouras J, Germanidis G, Paroutoglou G, Paikos D, Lazaraki G, Pilpilidis I, Chatzimavroudis G, Fasoulas K, Zavos C: Sequential or simultaneous placement of self-expandable metallic stents for palliation of malignant biliary and duodenal obstruction due to unresectable pancreatic head carcinoma. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential or simultaneous placement of self-expandable metallic stents for palliation of malignant biliary and duodenal obstruction due to unresectable pancreatic head carcinoma.
  • BACKGROUND: Pancreatic cancer is generally not amenable to curative resection, and self-expanding metallic stents have been used to relieve obstruction of bile duct and duodenum in patients with unresectable pancreatic cancer.
  • However, both relative experience with sequential or simultaneous endoscopic stents placement in biliary and duodenal stricture and long-term efficacy of these stents are limited.
  • The aim of this study was to present our experience on the effectiveness of this form of endoscopic treatment.
  • PATIENTS AND METHODS: We performed a retrospective review of all patients undergoing sequential or simultaneous biliary and duodenal stent placement for biliary and symptomatic duodenal obstruction due to unresectable pancreatic head carcinomas in 4 tertiary endoscopic centers.
  • RESULTS: Thirty-nine patients with unresectable pancreatic head cancer were included.
  • Biliary or duodenal stenting was unsuccessful in 7 patients (17.9%).
  • Twenty-one patients (65.6%) received at least first-line chemotherapy.
  • Median duodenal and biliary patency was 3 months (range: 1 to 12 mo) and 9 months (range: 2 to 22 mo), respectively (P<0.05).
  • No major complications or death occurred in relation to endoscopic treatment.
  • CONCLUSIONS: Placement of self-expandable metal stents is a safe and efficacious palliation method for biliary and duodenal obstruction due to unresectable pancreatic head carcinoma.
  • [MeSH-major] Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Catheterization. Cholangiopancreatography, Endoscopic Retrograde. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged. Palliative Care. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150420.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


71. Lamalmi N, Rouas L, Cherradi N, Malihy A, Khattab M, Alhamany Z: [Botryoid Wilms tumor extending into the duodenum]. Arch Pediatr; 2010 Dec;17(12):1664-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botryoid Wilms tumor extending into the duodenum].
  • We report on a rare case of botryoid Wilms tumor extending into the duodenum.
  • The main differential diagnosis of this unusual tumor is botryoid rhabdomyosarcoma.
  • The tumor was found to extend into the 2nd portion of the duodenum.
  • The pathologic diagnosis was mixed type nephroblastoma, SIOP 2001 stage III.
  • The patient was given a course of postoperative chemotherapy.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ureteral Neoplasms / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Diagnosis, Differential. Humans. Infant. Male. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Rhabdomyosarcoma / diagnosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20943355.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Gastrointestinal stromal tumor was observed in 80.0% (20/25), 72.0% (18/25) and 36.0% (9/25) of the patients, respectively.
  • Malignant lymphoma was demonstrated in 69.2% (9/13), 30.8% (4/13) and 0% (0/13) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


73. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Linfomas del tubo digestivo y glándulas anexas en pacientes con SIDA. Serie de casos.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • All patients were staged by computed tomography scanning and bone marrow examination, in addition to the endoscopic evaluation.
  • RESULTS: All patients were males; 4 were heterosexual, 2 homosexual, and 1 were a hemophilic and an intravenous drug abuser.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • All patients presented "B" symptoms at the time of diagnosis.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • Four patients were treated with systemic chemotherapy with granulocitic growth factor support plus highly active antiretroviral therapy (HAART); 2 of them (cavum and one of the colon) had a prolonged survival with immune reconstitution during 5 and 6 years, respectively, after the diagnosis.
  • The median survival of the patients, which received HAART plus chemotherapy, was 33 months.
  • Early diagnosis followed by chemotherapy plus HAART are necessary to improve the prognosis and the survival of these patients.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis


74. Sze DY: Targeted drug delivery for refractory hemorrhagic Crohn disease. J Vasc Interv Radiol; 2006 Jan;17(1):163-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted drug delivery for refractory hemorrhagic Crohn disease.
  • The present report describes a case of chronic hemorrhage from an inflamed duodenum that was refractory to all endoscopic and systemic therapies, which was successfully treated with chemoembolization of the pancreaticoduodenal arcade with use of corticosteroids and gelatin sponge.
  • The application of chemoembolization techniques need not be limited to treatment of malignancies.
  • [MeSH-major] Chemoembolization, Therapeutic. Crohn Disease / complications. Dexamethasone / therapeutic use. Gastrointestinal Hemorrhage / therapy. Gelatin Sponge, Absorbable. Glucocorticoids / therapeutic use
  • [MeSH-minor] Arteries / pathology. Duodenitis / etiology. Duodenitis / therapy. Duodenum / blood supply. Humans. Male. Middle Aged


75. Tulchinsky H, Keidar A, Strul H, Goldman G, Klausner JM, Rabau M: Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Arch Surg; 2005 Feb;140(2):159-63; discussion 164
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve patients had 14 desmoid tumors: 7 were treated surgically and 7 medically (these patients received celecoxib and tamoxifen citrate therapy).
  • Of the 41 patients who underwent upper gastrointestinal tract endoscopy, 11 developed duodenal and/or ampullary adenomas.
  • Two patients died--one of a huge mesenteric desmoid tumor and the other of an aggressive mesenteric malignant fibrous histiocytoma.
  • CONCLUSIONS: Long-term morbidity and mortality were strongly related to the development of mesenteric tumors and ampullary-duodenal polyps.
  • Early detection of desmoid tumors, duodenal, pouch, and rectal cuff adenomas by periodic computed tomography, gastroduodenoscopy, and pouchoscopy, respectively, may allow control by medical therapy, endoscopy, or limited surgical procedures.
  • In most patients control of desmoid tumors was achieved using a combination of celecoxib and tamoxifen citrate therapy.
  • [MeSH-minor] Adolescent. Adult. Celecoxib. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiography. Comorbidity. Drug Therapy, Combination. Endoscopy, Digestive System. Female. Fibromatosis, Aggressive / drug therapy. Fibromatosis, Aggressive / radiography. Fibromatosis, Aggressive / surgery. Humans. Male. Middle Aged. Pyrazoles / therapeutic use. Retrospective Studies. Sulfonamides / therapeutic use. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723997.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 094ZI81Y45 / Tamoxifen; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


76. Caudry M, Ratoanina JL, Escarmant P, Maire JP: [Target volume in radiotherapy of gastric adenocarcinoma]. Cancer Radiother; 2001 Oct;5(5):523-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les volumes-cibles de la radiothérapie des adénocarcinomes gastriques.
  • A GTV should be considered in preoperative or exclusive radiation therapy.
  • a) A "tumor bed" volume.
  • Parietal infiltration may extend beyond macroscopic limits of the tumor, especially in "linitis plastica".
  • Therefore this volume will include: the tumor and the remaining stomach or their "bed of resection", a part of the transverse colon, the duodenum, the pancreas and the truncus of the portal vein.
  • (1) contiguous microscopic extension from deeply invasive T3 and T4 tumors, that remain amenable to local sterilization with doses of 45-50 Gy, delivered in a CTV including the peritoneal cavity at the level of the gastric bed, and under the parietal incision;.
  • (2) true "peritoneal carcinomatosis", with widespread seeds, where chemotherapy (systemic or intraperitoneal) is more appropriate.
  • In distal and proximal tumors, involvement of resection margins is of poor prognosis--a radiation boost must be delivered at this level.
  • In tumors invading the distal esophagus, a more complete coverage of mediastinal lymph nodes should be considered, especially in patients in good general condition.
  • In contrast, for distal tumors, the hepatic pedicle and the hepatoduodenal ligament should be included whereas the splenic area could be spared.
  • CONCLUSION: Planning the treatment of gastric cancer remains difficult; target volumes must be customized by experienced radiation oncologists according to tumoral and clinical situation.
  • [MeSH-minor] Dose Fractionation. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm, Residual

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11715304.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


77. Akamatsu T, Kaneko Y, Ota H, Miyabayashi H, Arakura N, Tanaka E: Usefulness of double balloon enteroscopy and video capsule endoscopy for the diagnosis and management of primary follicular lymphoma of the gastrointestinal tract in its early stages. Dig Endosc; 2010 Jan;22(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of double balloon enteroscopy and video capsule endoscopy for the diagnosis and management of primary follicular lymphoma of the gastrointestinal tract in its early stages.
  • Furthermore, we estimate the effectiveness of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) including rituximab for them.
  • METHODS: Thirteen consecutive patients who were diagnosed of having FL in the duodenum between July 2005 and September 2008 were studied.
  • Chemotherapy was performed after written informed consent.
  • Eleven of 13 patients finally received chemotherapy, and all of them achieved complete regression.
  • CONCLUSION: Total examination of the small intestine using DBE should be performed before treatment to choose a suitable treatment procedure for primary FL of the GI tract.
  • Chemotherapy is effective to achieve complete regression of primary FL of the GI tract.
  • [MeSH-major] Capsule Endoscopy. Endoscopy, Gastrointestinal. Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Duodenal Neoplasms / diagnosis. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Female. Humans. Ileal Neoplasms / diagnosis. Ileal Neoplasms / pathology. Jejunal Neoplasms / diagnosis. Jejunal Neoplasms / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078662.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


78. Hayashi Y, Yamamoto H, Taguchi H, Sunada K, Miyata T, Yano T, Arashiro M, Sugano K: Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease. J Gastroenterol; 2009;44 Suppl 19:57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease.
  • BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) occasionally induce small-bowel injury.
  • The aim of this study was to clarify the clinical features of the disease and evaluate the effectiveness of endoscopic balloon dilation therapy for diaphragm disease, using double-balloon endoscopy (DBE).
  • (3) improvement in clinical findings (signs and symptoms) and/or endoscopic findings by cessation of NSAIDs, except for diaphragm disease; and (4) exclusion of other causes (e.g., malignant tumor, inflammatory bowel disease, and infectious disease).
  • For localized lesions, 12 patients evidenced lesions in the ileum, 5 patients had lesions in the duodenum and/or jejunum, and 1 had lesions in both intestines.
  • The endoscopic balloon dilation appears to be a safe and effective treatment for diaphragm disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization / instrumentation. Databases, Factual. Duodenum / drug effects. Duodenum / pathology. Female. Humans. Ileum / drug effects. Ileum / pathology. Jejunum / drug effects. Jejunum / pathology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 1999 Dec;40(6):517-24 [10660951.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):749-54 [1501650.001]
  • [Cites] Endoscopy. 2007 Dec;39(12):1068-71 [18072058.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Sep;5(9):1040-5 [17625980.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):1038-41 [17963892.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):1014-7 [17140921.001]
  • [Cites] Prostaglandins. 1977 Aug;14(2):333-41 [331401.001]
  • [Cites] Aliment Pharmacol Ther. 2000 May;14(5):639-50 [10792129.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):109-17 [8978349.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):848-51 [15557976.001]
  • [Cites] Gut. 1990 Jul;31(7):777-80 [1973396.001]
  • [Cites] Gastroenterology. 1988 Apr;94(4):1070-4 [3345876.001]
  • [Cites] Gastroenterology. 1967 Dec;53(6):856-67 [4863722.001]
  • [Cites] J Gastroenterol Hepatol. 2006 May;21(5):922-3 [16704551.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9 [15645405.001]
  • [Cites] World J Gastroenterol. 2005 Aug 21;11(31):4861-4 [16097059.001]
  • [Cites] Dig Surg. 2002;19(5):410-3 [12435916.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):328; discussion 328 [16427948.001]
  • [Cites] Scand J Gastroenterol. 2008;43(4):490-6 [18365915.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1010-6 [15551254.001]
  • [Cites] Am J Gastroenterol. 1992 Sep;87(9):1183-6 [1519577.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E196-7 [17614060.001]
  • [Cites] Gut. 2008 Feb;57(2):181-7 [17639086.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3 Suppl):S34-8 [17709028.001]
  • [Cites] Gut. 2001 Feb;48(2):163-7 [11156635.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1556; author reply 1556-7 [14628813.001]
  • [Cites] Arch Surg. 2005 Dec;140(12):1162-6 [16365236.001]
  • [Cites] J Am Coll Surg. 1997 Sep;185(3):250-4 [9291402.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1145-50 [15509673.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1172-8 [15887101.001]
  • [Cites] Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22 [17451567.001]
  • [Cites] Gut. 2006 Sep;55(9):1372 [16905713.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):516-26 [3384981.001]
  • [Cites] Gut. 1992 Sep;33(9):1204-8 [1427372.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41 [15704047.001]
  • (PMID = 19148795.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


79. Bixquert Jiménez M: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig; 2009 Aug;101(8):553-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
  • Irritable bowel syndrome (IBS) is the most common functional digestive disorder, and may affect 11-20% of the adult population in industrialized countries.
  • The disorder is difficult to treat, and the wide spectrum of non-drug and drug treatments shows our ignorance about the cause of the condition.
  • Newer drugs, both pro- and anti-serotonin, have failed to show long-term efficacy or have been withdrawn due to concerns about harmful effects.
  • Although results between studies are difficult to compare because of differences in study design, probiotic dose, strain, and duration of therapy, some studies show symptom improvement.
  • Lactobacilli are found among the normal bacterial flora of the gastrointestinal tract, and Lactobacillus plantarum (Lp) is one of the species frequently isolated from the human mucosa, which is capable of surviving the low pH of the stomach and duodenum, resisting the effect of bile acids in the upper small intestine when ingested, and temporarily colonizing the gastrointestinal tract by binding to the intestinal and colonic mucosa.
  • [MeSH-major] Intestines / microbiology. Irritable Bowel Syndrome / etiology. Irritable Bowel Syndrome / therapy. Probiotics / therapeutic use
  • [MeSH-minor] Adult. Bifidobacterium. Clinical Trials as Topic. Clostridium difficile. Diarrhea / therapy. Enterocolitis, Pseudomembranous / therapy. Female. Humans. Intestinal Mucosa / microbiology. Lactobacillus. Male. Prevalence. Spain / epidemiology. Travel. Treatment Outcome

  • Genetic Alliance. consumer health - Irritable Bowel Syndrome.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785495.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 76
  •  go-up   go-down


80. Fujiwara Y, Taniguchi H, Kimura Y, Takiguchi S, Yasuda T, Yano M, Monden M: [Two advanced gastric cancer patients who showed malignant ileus soon after administration of combination therapy of preoperative intra-peritoneal chemotherapy and gastrectomy]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1614-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two advanced gastric cancer patients who showed malignant ileus soon after administration of combination therapy of preoperative intra-peritoneal chemotherapy and gastrectomy].
  • Forty-eight patients with serosa-invaded advanced gastric cancer were administered to pre-operative intra-peritoneal chemotherapy to prevent peritoneal recurrence.
  • There were no severe adverse effects from the intra-peritoneal chemotherapy.
  • Of these patients, 2 showed malignant ileus shortly after intra-peritoneal chemotherapy and gastrectomy, and needed laparotomy because of dilatation of duodenum stump and liver dysfunction.
  • We report the clinicopathological features of these cases and therapeutic limitation of intra-peritoneal chemotherapy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gastrectomy. Ileus / etiology. Injections, Intraperitoneal / adverse effects. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Invasiveness. Preoperative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Pozzetto B, Guarino G, Tonello C, Liguori G: [Treatment of adenocarcinoma of the duodenum: presentation of 4 clinical cases and review of the literature]. Chir Ital; 2002 Mar-Apr;54(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adenocarcinoma of the duodenum: presentation of 4 clinical cases and review of the literature].
  • [Transliterated title] Trattamento dell'adenocarcinoma del duodeno: presentazione di quattro casi clinici e revisione della letteratura.
  • The Authors comment on the difficulty of diagnosing and treating duodenal tumours.
  • The Authors report 4 cases of primitive adenocarcinoma of the duodenum treated by pancreaticoduodenectomy (2 cases), segmental resection (1 case) and palliative surgery (1 case) for the presence of omental and lymph-node metastases.
  • Survival was 18 and 14 months in the patients who underwent pancreaticoduodenectomy and 9 months for the patient receiving palliative treatment; the patient who underwent segmental resection is still alive and healthy after 12 months.
  • The Authors point out that adenocarcinoma of the duodenum is an uncommon neoplasm and stress the difficulty encountered in establishing an accurate diagnosis and appropriate surgical management.
  • Better results can be obtained only with an early diagnosis.
  • Chemotherapy and radiotherapy do not significantly improve survival.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12038110.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 41
  •  go-up   go-down


82. Rapozzi V, Zacchigna M, Biffi S, Garrovo C, Cateni F, Stebel M, Zorzet S, Bonora GM, Drioli S, Xodo LE: Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a. Cancer Biol Ther; 2010 Sep 1;10(5):471-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a.
  • The design of new photosensitizers with enhanced phototoxicity and pharmacokinetic properties remains a central challenge for cancer photodynamic therapy (PDT).
  • In this study, Pheophorbide a (Pba) has been pegylated to methoxypolyethylene glycol (mPE G-Pba) to produce a soluble photosensitizer that exhibits a higher tissue distribution than free Pba.
  • In vitro studies have shown that mPE G-Pba promotes a fairly strong photosensitizing effect in cancer cells, as previously observed for the unpegylated molecule. mPE G-Pba targets the mitochondria where, following photoactivation, ROS are produced which cause a cellular injury by lipid peroxidation.
  • The effect of pegylation on the photosensitizer biodistribution has been examined in different selected organs of female mice, at different time points after intraperitoneal administration of the drug (50 μmol/Kg body weight).
  • Other than free Pba, which showed a low tissue accumulation, mPE G-Pba has been detected in significant amounts (8 to 16 μg/ml) in liver, spleen, duodenum and kidney and, 3-5 hours after intraperitoneal injection, in moderate amounts (3 to 8 μg/ml) in brain and lung.
  • In vivo optical imaging performed on living female C57/BL6 mice bearing a subcutaneous melanoma mass, showed that injected mPEG-Pba distributes all over the body, with an higher uptake in the tumor respect to free Pba.
  • Our results indicate that although pegylation somewhat decreases the phototoxicity, it significantly increases the drug solubility and tissue distribution and tumor uptake of mPE G-Pba, making the conjugate an interesting photosensitizer for PDT.
  • [MeSH-minor] Animals. Female. HeLa Cells. Hep G2 Cells. Humans. Injections, Intraperitoneal. Malondialdehyde / analysis. Mice. Mitochondrial Membranes / metabolism. Reactive Oxygen Species. Tissue Distribution. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592494.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Reactive Oxygen Species; 1406-65-1 / Chlorophyll; 30IQX730WE / Polyethylene Glycols; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


83. Das BC, Kawarada Y: Long-term survival after treatment of gastric carcinoma with liver metastases. A case report. Hepatogastroenterology; 2003 Nov-Dec;50(54):2282-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after treatment of gastric carcinoma with liver metastases. A case report.
  • Radiographic and endoscopic studies showed a Borrmann type I gastric carcinoma on the anterior surface of the body of the stomach near the greater curvature, and a metastatic work-up demonstrated two masses in the right lobe of the liver (segment 6 and 8).
  • The preoperative diagnosis was gastric carcinoma with liver metastasis (stage IV).
  • Ligation of the right portal vein and intraoperative common hepatic artery chemotherapy (one shot) was performed to destroy any non-visible metastatic tumors in the right lobe of the liver.
  • An aneurysm of the common hepatic artery developed after another shot of chemotherapy through the celiac artery one month after the operation.
  • The aneurysm ruptured, and a small fistula formed between the aneurysm and the duodenum.
  • The aneurysm was successfully treated by aneurysmectomy, and the perforated duodenal wall was managed by catheter duodenostomy.
  • The patient is alive and pursuing his previous occupation with no evidence of tumor recurrence.
  • Removal of the primary and metastatic lesions with portal vein ligation and intra-arterial chemotherapy is therefore effective as an active measure to prolong the survival time of gastric carcinoma patients with metastases limited to a single lobe of the liver.
  • [MeSH-minor] Aneurysm, Ruptured / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Hepatic Artery / surgery. Humans. Jejunostomy. Ligation. Male. Middle Aged. Portal Vein / surgery. Postoperative Complications / surgery. Reoperation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14696518.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


84. Souzaki R, Tajiri T, Kinoshita Y, Tanaka S, Koga Y, Suminoe A, Hara T, Kohashi K, Oda Y, Taguchi T: Successful treatment of advanced pancreatoblastoma by a pylorus-preserving pancreatoduodenectomy after radiation and high-dose chemotherapy. Pediatr Surg Int; 2010 Oct;26(10):1045-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of advanced pancreatoblastoma by a pylorus-preserving pancreatoduodenectomy after radiation and high-dose chemotherapy.
  • BACKGROUND: Pancreatoblastoma (PB) is a rare malignant pancreatic tumor in children and approximately 200 cases have been reported in the literature.
  • The overall 5-year survival rate in PB is 43-50% and no standard treatment for PB has been established.
  • This report presents the case of a 6-year-old female with advanced PB treated successfully by a pylorus-preserving pancreatoduodenectomy (PPPD) after induction chemotherapy, radiation and stem cell transplantation (SCT).
  • Abdominal computed tomography (CT) scan showed a 9-cm heterogeneous mass located at the pancreatic head and body, and the duodenum was completely compressed.
  • The inferior vena cava, superior mesenteric artery, and vein were encased by the tumor.
  • The tumor had well-defined margins and calcification.
  • Initially, a resection of the tumor was impossible.
  • An open biopsy was performed and the histopathological diagnosis was PB.
  • She underwent five cycles of the induction chemotherapy regimen for advanced neuroblastoma (cyclophosphamide, etoposide, vincristine, pirarubicin and cisplatin), and the tumor size was decreased to a diameter of 7.5 cm.
  • Furthermore, chemotherapy with irinotecan and vincristine, radiotherapy (40 Gy) and SCT (etoposide, carboplatin, melphalan) was administered.
  • The serum AFP level decreased to 41.1 ng/ml, and the tumor size was decreased to a diameter of 6.5 cm.
  • Then she underwent a PPPD and the tumor was completely resected.
  • The child was administered mild postoperative chemotherapy using irinotecan and has been disease-free for 4 months and, and her serum AFP levels remain within normal values.
  • The combined therapy including the intensive chemotherapy with SCT and the radiation followed by surgical treatment is thought to be effective for the treatment of advanced PB.
  • [MeSH-minor] Child. Female. Follow-Up Studies. Humans. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy. Pancreatic Neoplasms / surgery. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2010 May;54(5):675-80 [19998473.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):604-6 [16282892.001]
  • [Cites] Arch Iran Med. 2009 Jan;12(1):69-72 [19111033.001]
  • [Cites] J Pediatr Surg. 2006 Mar;41(3):596-8 [16516645.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):362-9 [17264331.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1841-4 [8792711.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] J Pediatr Surg. 2005 Aug;40(8):1341-4 [16080945.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] JOP. 2009 Mar 09;10 (2):192-5 [19287117.001]
  • [Cites] Pancreatology. 2004;4(5):441-51; discussion 452-3 [15256806.001]
  • [Cites] JOP. 2009 Sep 04;10(5):492-5 [19734623.001]
  • [Cites] Cancer. 1977 Jan;39(1):247-54 [188539.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6(6):369-72 [9007475.001]
  • [Cites] Med Pediatr Oncol. 1996 Sep;27(3):193-7 [8699999.001]
  • (PMID = 20632017.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Pancreatoblastoma
  •  go-up   go-down


85. Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Cho SW, Hahm KB: Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment. Free Radic Biol Med; 2001 Apr 15;30(8):905-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative damages are critical in pathogenesis of reflux esophagitis: implication of antioxidants in its treatment.
  • BACKGROUND: The facts that the severity of reflux esophagitis cannot be accurately predicted on the basis of acid exposure and acid suppression treatment is not enough for the complete healing, suggested that other damaging factors might be involved in pathogenesis of reflux esophagitis.
  • AIMS: The present study was designed to evaluate the oxidative stress as the major pathogenic factor of reflux esophagitis and the importance of antioxidant in treatment of reflux esophagitis.
  • MATERIALS AND METHODS: Reflux esophagitis was induced by the insertion of small caliber ring (3 mm in diameter) into the duodenum 1 cm distal to the ligament of Treitz in rats.
  • Severe, hemorrhagic, and longitudinal ulcerations were developed in H2-RA pretreated group, whereas mildly scattered erosions were observed in antioxidant-pretreated group.
  • H2-RA treatment didn't affect the levels of GSH and MDA, whereas DA-9601 attenuated the decrement of the GSH levels and significantly decreased lipid peroxides in the esophagus.
  • Antioxidants treatment showed significant reductions in the activation of NF-kappaB, inflammation-associated transcription factor, especially p50 component in accordance with significant higher levels of NF-kappaB repressor, IkappaBalpha expression.
  • CONCLUSION: Oxygen-derived free radicals seem to be one of the important mediators in generation of reflux esophagitis, which suggests that the combination of antioxidant and anti-secretory medications will be ideal and more beneficial in the prevention and treatment of reflux esophagitis than currently prescribed antisecretory treatment alone.
  • [MeSH-major] Antioxidants / therapeutic use. Esophagitis, Peptic / drug therapy. Esophagitis, Peptic / metabolism. Esophagus / pathology. I-kappa B Proteins. Oxidative Stress
  • [MeSH-minor] Animals. Anti-Ulcer Agents / pharmacology. Anti-Ulcer Agents / therapeutic use. Blotting, Western. Cyclooxygenase 2. DNA / genetics. DNA / metabolism. DNA-Binding Proteins / metabolism. Electrophoresis, Polyacrylamide Gel. Gastric Acid / metabolism. Glutathione / metabolism. Inflammation / drug therapy. Inflammation / metabolism. Inflammation / pathology. Isoenzymes / metabolism. Lipid Peroxides / metabolism. Male. Malondialdehyde / metabolism. NF-kappa B / metabolism. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase Type II. Pharmaceutical Preparations. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Prostaglandin-Endoperoxide Synthases / metabolism. Ranitidine / pharmacology. Ranitidine / therapeutic use. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. RANITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295533.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Antioxidants; 0 / DA 9601; 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 0 / Isoenzymes; 0 / Lipid Peroxides; 0 / NF-kappa B; 0 / Pharmaceutical Preparations; 0 / Plant Extracts; 139874-52-5 / NF-kappaB inhibitor alpha; 4Y8F71G49Q / Malondialdehyde; 884KT10YB7 / Ranitidine; 9007-49-2 / DNA; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, rat; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; GAN16C9B8O / Glutathione
  •  go-up   go-down


86. Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM: Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol; 2009 May 11;9:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics.
  • BACKGROUND: We have previously demonstrated the clinical efficacy of montelukast in a randomized double-blind controlled cross-over trial in patients with dyspepsia in association with duodenal eosinophilia.
  • Eighteen of these patients had elevated duodenal eosinophil density and underwent repeat blood sampling and endoscopy following 21 days of therapy with montelukast (10 mg/day).
  • The following were determined: global clinical response on a 5-point Lickert-type scale, eosinophil density utilizing H & E staining, eosinophil activation determined by degranulation indices on electron microscopy, and serum cytokine concentrations.
  • On day 21, pharmacokinetics and duodenal mucosal drug concentrations were determined.
  • The response was unrelated to systemic drug exposure or to mucosal drug concentration.
  • Other than a mild decrease in eosinophil density in the second portion of the duodenum, there were no significant changes in eosinophil density, eosinophil activation, or serum cytokine concentrations following treatment with montelukast.
  • Pre-treatment TNF-alpha concentration was negatively correlated with clinical response.
  • [MeSH-major] Acetates / pharmacokinetics. Acetates / therapeutic use. Duodenum / pathology. Dyspepsia / drug therapy. Eosinophilia / drug therapy. Leukotriene Antagonists / pharmacokinetics. Leukotriene Antagonists / therapeutic use. Quinolines / pharmacokinetics. Quinolines / therapeutic use
  • [MeSH-minor] Adolescent. Biopsy. Cell Count. Child. Cytokines / blood. Dose-Response Relationship, Drug. Eosinophils / drug effects. Eosinophils / pathology. Female. Humans. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Dyspepsia.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Indigestion.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MONTELUKAST .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2001 May;56(5):341-4 [11312400.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2634-40 [18320315.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):583-92 [11877481.001]
  • [Cites] Paediatr Drugs. 2002;4(2):123-39 [11888359.001]
  • [Cites] Thorax. 2002 Sep;57(9):774-8 [12200521.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):329-33 [12352522.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G154-64 [12388180.001]
  • [Cites] Eur J Pharmacol. 2003 Jan 10;459(1):27-39 [12505531.001]
  • [Cites] Gut. 2003 Feb;52(2):181-5 [12524397.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):293-4 [12548071.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9 [15017654.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):343-51 [15076638.001]
  • [Cites] J Clin Pharmacol. 2004 May;44(5):487-94 [15102869.001]
  • [Cites] Life Sci. 1983 Nov 21;33(21):2121-7 [6645792.001]
  • [Cites] Am J Physiol. 1989 Dec;257(6 Pt 1):G860-4 [2558578.001]
  • [Cites] Can J Physiol Pharmacol. 1993 Feb;71(2):145-50 [8391373.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Jul;274(1):72-7 [7616450.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 May;355(5):625-30 [9151302.001]
  • [Cites] Gastroenterology. 1998 Oct;115(4):919-28 [9753495.001]
  • [Cites] J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):506 [10452782.001]
  • [Cites] Gut. 1999 Sep;45 Suppl 2:II60-8 [10457047.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 Jun;94(6):670-4 [15984600.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):291-5 [16131983.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 Oct;95(4):372-80 [16279568.001]
  • [Cites] Neurogastroenterol Motil. 2006 Jan;18(1):6-17 [16371078.001]
  • [Cites] Pediatr Allergy Immunol. 2006 Jun;17(4):250-8 [16771778.001]
  • [Cites] Clin Exp Allergy. 2006 Jun;36(6):689-703 [16776669.001]
  • [Cites] Allergy Asthma Proc. 2006 Jul-Aug;27(4):383-6 [16948354.001]
  • [Cites] Eur J Pharmacol. 2006 Oct 24;548(1-3):158-66 [16949072.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4840-8 [17878383.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83 [17686660.001]
  • [Cites] Dig Dis Sci. 2001 Aug;46(8):1787-90 [11508684.001]
  • (PMID = 19432972.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00148603
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acetates; 0 / Cytokines; 0 / Leukotriene Antagonists; 0 / Quinolines; MHM278SD3E / montelukast
  • [Other-IDs] NLM/ PMC2685805
  •  go-up   go-down


87. Babak OIa: [The treatment of peptic ulcer patients with a disordered motor-evacuatory function of the digestive canal]. Lik Sprava; 2000 Mar;(2):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of peptic ulcer patients with a disordered motor-evacuatory function of the digestive canal].
  • Submitted in the paper are basic mechanisms of development of disorders of gastrointestinal motility and evacuatory function in ulcer of the stomach and duodenum.
  • Pharmacological correction of the above disorders is considered in some detail and discussed as thoroughly as possible.
  • Ways for enhancement of motility and normalization of the evacuatory function of the stomach and duodenum are outlined, indications and contraindications are determined, specificities of each of the drugs employed are described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10862479.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Gastrointestinal Agents
  •  go-up   go-down


88. Glaser M, Roskar Z, Skalicky M, Krajnc I: Cystic dystrophy of the duodenal wall in a heterotopic pancreas. Wien Klin Wochenschr; 2002 Dec 30;114(23-24):1013-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic dystrophy of the duodenal wall in a heterotopic pancreas.
  • Cystic dystrophy of the duodenal wall in heterotopic pancreas is a rare disease affecting younger men in particular.
  • On account of its difficult diagnosis and nonspecific signs, it was first described in 1970.
  • Barium meal and esophagogastroduodenoscopy revealed a severe deformation of the duodenum.
  • Biopsy of the duodenal mucosa detected moderate inflammatory changes.
  • Ultrasound examination showed cystic changes in the duodenal wall and in the vicinity of the head of the pancreas.
  • Only with the aid of endoscopic ultrasound, could bizarre cystic changes in the submucosa of the duodenal wall be detected, which was also confirmed by computer tomography.
  • Duodenal biopsy also does not reveal its cause since the typical lesions lie deeper in the submucosa or muscularis propria.
  • The anomaly involves, above all, the stomach and duodenum.
  • Prior to the introduction of imaging techniques such as endoscopic ultrasonography, computer tomography and nuclear magnetic resonance, the diagnosis could only be made by means of an operative procedure.
  • Treatment is primarily surgical; smaller cysts can be treated by endoscopic fenestration.
  • Pharmacological treatment with somatostatin is rarely performed.
  • [MeSH-major] Choristoma. Cysts. Duodenal Diseases. Pancreas
  • [MeSH-minor] Abdominal Pain / drug therapy. Abdominal Pain / etiology. Endoscopy. Hormones / administration & dosage. Hormones / therapeutic use. Humans. Injections, Subcutaneous. Male. Middle Aged. Somatostatin / administration & dosage. Somatostatin / therapeutic use. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635471.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Hormones; 51110-01-1 / Somatostatin
  •  go-up   go-down


89. Du Z, Chen J, Zhou X, Zhang T, Chen B, Tang F: Composite lymphoma with relapse of enteropathy-type T-cell lymphoma. Leuk Lymphoma; 2009 May;50(5):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite lymphoma with relapse of enteropathy-type T-cell lymphoma.
  • We describe an unusual case of with de novo composite diffuse large B-cell lymphoma and enteropathy-type T-cell lymphoma involving the duodenum in a 65-year-old man with celiac disease.
  • A segmental duodenum resection revealed that two neoplastic components had infiltrated the intestinal wall.
  • After chemotherapy, the patient experienced two relapses of enteropathy-type T-cell lymphoma only.
  • We review the medical literature on composite B- and T-cell lymphomas and discuss their diagnosis, pathogenesis, prognosis and treatment.
  • [MeSH-minor] Aged. Duodenal Neoplasms / pathology. Duodenum / pathology. Humans. Male. Neoplasm Invasiveness. Neoplasms, Second Primary. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330653.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 41
  •  go-up   go-down


90. Yasuda S, Hoshikawa T, Yazawa N, Fukumitsu H, Ishikawa K, Suzuki T, Sadahiro S, Shimakura Y, Shibuya M, Nasu S, Tajima T, Makuuchi H: A case of duodenal involvement of multiple myeloma imaged by positron emission tomography with 18F-fluorodeoxyglucose. Tokai J Exp Clin Med; 2001 Dec;26(4-6):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of duodenal involvement of multiple myeloma imaged by positron emission tomography with 18F-fluorodeoxyglucose.
  • A 61-year-old woman had been treated for multiple myeloma for 4 years when she developed abdominal pain.
  • Ultrasonography and computed tomography revealed a tumor in the abdomen.
  • Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) showed increased FDG uptake in the tumor.
  • In previous bone marrow lesions, which were in clinical remission after chemotherapy and radiotherapy, abnormal FDG uptake was not recognized.
  • Pathological examination after surgery revealed the tumor to be a plasmacytoma of the duodenum.
  • Plasmacytoma of the duodenum is rare but can be seen during the clinical course of multiple myeloma.
  • [MeSH-major] Duodenal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Multiple Myeloma. Neoplasms, Second Primary / radionuclide imaging. Plasmacytoma / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Female. Humans. Middle Aged. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12030445.001).
  • [ISSN] 0385-0005
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 13
  •  go-up   go-down


91. Perna AG, Jones DM, Duvic M: Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma; 2004 Dec;5(3):190-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that exists on a spectrum of diseases with cutaneous CD30+ anaplastic large-cell lymphoma (ALCL).
  • Multiple treatment options are available, although none are curative.
  • A 43-year-old man developed lymphomatoid papulosis lesions at 3 years of age, which persisted into adulthood, and he later developed ALCL of the duodenum.
  • Treatment with standard CHOP (cyclophosphamide/doxorubicin/vincristine/prednisolone) chemotherapy resulted in complete remission of his gastrointestinal lymphoma and temporary improvement of his skin lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Intestinal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphomatoid Papulosis / pathology. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Adult. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


92. Ito Y, Suzuki M, Oyamada Y, Kou H, Takeshita K, Asano K, Yamaguchi K: [A case of relapsed small cell lung cancer recognized by simple metastasis to the duodenum]. Nihon Kokyuki Gakkai Zasshi; 2001 Jan;39(1):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of relapsed small cell lung cancer recognized by simple metastasis to the duodenum].
  • We describe a case of relapsed small cell lung cancer (SCLC) recognized by a duodenal tumor, its probable metastasis.
  • A diagnosis of SCLC of the left lung invading the mediastinum was based on a transesophageal biopsy.
  • Chemotherapy consisting of CDDP and VP-16 followed by thoracic irradiation at a total dose of 50 Gy was performed from October 1996 to August 1997, resulting in CR (Complete Response) of the tumor.
  • In April of 1999, a mass surrounding the duodenum was found through an abdominal CT survey for tumor relapse, but no other tumors were detected in a series of CT scans or inbone scintigraphy.
  • Subsequent fiberscopy of the upper gastrointestinal tract revealed an ulcerative tumor extensively invading the mucosa of the duodenal bulb.
  • Biopsy specimens obtained from the duodenal tumor showed small-cell carcinoma with features similar to those of SCLC found in 1996, suggesting that SCLC of the left lung metastasized to the duodenal wall.
  • Chemoradiotherapy with 4 cycles of CDDP and VP-16 followed by abdominal irradiation at a dose of 30 Gy was given again from May to September 1999, producing good PR (Partial Response).
  • Although metastasis of SCLC to the duodenum seldom occurs, this report indicates that its early detection and effective treatment may prevent serious symptoms caused by obstruction of the duodenum or the papilla Vater.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Duodenal Neoplasms / secondary. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296383.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


93. Telford JJ, Carr-Locke DL, Baron TH, Tringali A, Parsons WG, Gabbrielli A, Costamagna G: Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc; 2004 Dec;60(6):916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study.
  • BACKGROUND: Endoscopic placement of self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction is safe and feasible.
  • METHODS: Patients with malignant gastric outlet obstruction undergoing enteral stent insertion were identified from endoscopy databases.
  • Obstruction was caused by cancer of the pancreas in 84, the stomach in 20, the bile duct in 15, the major duodenal papilla in 8, another primary site in 16, and metastases in 33.
  • The site of obstruction was the duodenum in 125, the distal stomach in 17, the stomach and the duodenum in 18, and surgical anastomosis in 16 patients.
  • Of the remaining 159 patients, 133 resumed oral intake for a median time of 146 days: 95% CI [65, 202].
  • On regression analysis, chemotherapy after stent placement was associated with prolonged duration of oral intake (hazard ratio 0.41: 95% CI [0.23, 0.72]).
  • CONCLUSIONS: After enteral stent insertion for malignant gastric outlet obstruction, 84% of patients resumed oral intake for a median time of 146 days.
  • Chemotherapy after enteral stent insertion was independently associated with prolongation of oral intake.
  • [MeSH-major] Digestive System Neoplasms / complications. Gastric Outlet Obstruction / therapy. Gastroscopy. Metals. Palliative Care. Stents. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Enteral Nutrition / statistics & numerical data. Female. Humans. Male. Middle Aged. Multivariate Analysis. Outcome and Process Assessment (Health Care) / statistics & numerical data. Radiotherapy, Adjuvant. Recurrence. Regression Analysis. Retreatment. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605006.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


94. Shelat VG, Diddapur RK: Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient. Singapore Med J; 2008 Aug;49(8):e198-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal carcinoid: a rare cause of melaena in a cirrhotic patient.
  • Laboratory tests and diagnostic imaging are of help in diagnosis.
  • These are indolent tumours and hence role of chemotherapy is limited.
  • Radionuclide and biological therapies are emerging.
  • We report a 29-year-old man presenting with melaena and diagnosed as having a neuroendocrine tumour of the duodenum together with liver cirrhosis.
  • Standard Whipple's procedure was done and he is doing well at follow-up.
  • [MeSH-major] Carcinoid Tumor / complications. Duodenal Neoplasms / complications. Liver Cirrhosis / diagnosis. Liver Cirrhosis / therapy. Melena / diagnosis. Melena / etiology. Neuroendocrine Tumors / complications
  • [MeSH-minor] Adult. Duodenum / pathology. Endoscopy / methods. Humans. Male. Neoplasm Metastasis. Prognosis. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756332.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


95. Chang SF, Chang HY, Tong YC, Chen SH, Hsaio FC, Lu SC, Liaw J: Nonionic polymeric micelles for oral gene delivery in vivo. Hum Gene Ther; 2004 May;15(5):481-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the delivered lacZ gene in various tissues of nude mice was assessed qualitatively by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside staining of sections and quantitatively by measuring enzyme activity in tissue extracts, using the substrate of beta-galactosidase, chlorophenol red-beta-D-galactopyranoside.
  • In addition, the types of cells expressing the lacZ gene in the duodenum were identified by histological analysis.
  • Duodenal penetration of DNA/PEO-PPO-PEO polymeric micelles was evaluated in vitro by calculating the apparent permeability coefficient.
  • After oral administration of six doses at 8-hr intervals, the highest expression of transferred gene lacZ was seen 48 hr after administration of the first dose, with gene expression detected in the villi, crypts, and goblet cells of the duodenum and in the crypt cells of the stomach.
  • Reporter gene activity was seen in the duodenum, stomach, and liver.
  • [MeSH-minor] Administration, Oral. Animals. Dose-Response Relationship, Drug. Duodenum / cytology. Edetic Acid / pharmacology. Endocytosis / drug effects. Epithelial Cells / metabolism. Feasibility Studies. Light. Male. Mice. Mice, Nude. Microscopy, Atomic Force. Oligopeptides / pharmacology. Particle Size. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / chemistry. Propylene Glycols / administration & dosage. Propylene Glycols / chemistry. Reverse Transcriptase Polymerase Chain Reaction. Scattering, Radiation. Tight Junctions / drug effects. Tissue Distribution. Transgenes

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15144578.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Micelles; 0 / Oligopeptides; 0 / PEO-PPO-PEO; 0 / Polymers; 0 / Propylene Glycols; 30IQX730WE / Polyethylene Glycols; 99896-85-2 / arginyl-glycyl-aspartic acid; 9G34HU7RV0 / Edetic Acid
  •  go-up   go-down


96. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull; 2002 Nov;25(11):1391-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multidrug resistance, but over the last decade, it has been elucidated that human MDR1 is also expressed throughout the body to confer intrinsic resistance to the tissues by exporting unnecessary or toxic exogeneous substances or metabolites.
  • A number of structurally unrelated drugs are substrates for MDR1, and MDR1 and other transporters are recognized as an important class of proteins for regulating pharmacokinetics and pharmacodynamics.
  • They also indicated that a polymorphism in exon 26 at position 3435 (C3435T), a silent mutation, affected the expression level of MDR1 protein in duodenum, and thereby the intestinal absorption of digoxin.
  • In this review, published reports are summarized for the future individualization of pharmacotherapy based on MDR1 genotyping.
  • [MeSH-minor] Animals. Genotype. Humans. Substrate Specificity / drug effects

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12419946.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein
  • [Number-of-references] 172
  •  go-up   go-down


97. Houissa F, Bouzaidi S, Mouelhi L, Ben Rejeb M, Moussa A, Mekki H, Dabbeche R, Trabelsi S, Said Y, Salem M, Najjar T: Diffuse primary malignant melanoma of the upper gastrointestinal tract. Gastroenterol Clin Biol; 2010 Jan;34(1):85-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse primary malignant melanoma of the upper gastrointestinal tract.
  • Primary malignant melanomas of the GI tract are very rare.
  • Theses lesions were found in the oesophagus, the stomach, the bulb and the duodenum.
  • Immunohistochemically, tumour cells were positive for HMB-45.
  • Palliative chemotherapy was not possible because patient was extremely cachectic and she died one month later.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Melanoma / diagnosis

  • Genetic Alliance. consumer health - Primary gastrointestinal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19864103.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Turcu AF, White JA, Kulaga ME, Skluth M, Gruss CB: Calcium channel blocker-associated small bowel angioedema. J Clin Gastroenterol; 2009 Apr;43(4):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An esophagogastroduodenoscopy showed patchy edematous, violaceous folds in the second portion of the duodenum.
  • Colonoscopy revealed a markedly edematous and erythematous distal ileum.
  • The discontinuation of the involved medication is the key for both diagnosis and treatment.
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / drug therapy. Abdominal Pain / radiography. Diarrhea / diagnosis. Diarrhea / drug therapy. Diarrhea / radiography. Female. Humans. Intestinal Diseases / chemically induced. Intestinal Diseases / radiography. Middle Aged

  • Hazardous Substances Data Bank. AMLODIPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077729.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 1J444QC288 / Amlodipine
  • [Number-of-references] 30
  •  go-up   go-down


99. Robinson A, Clark WF: A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura). J Gastrointest Cancer; 2010 Mar;41(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura).
  • INTRODUCTION: Adenocarcinoma of the duodenum is a rare cancer and not submitted to the type of clinical trials that guide chemotherapy treatments in other gastrointestinal malignancies.
  • CASE REPORT: This case demonstrates the potential use for gemcitabine, a chemotherapy typically used in pancreas and biliary tract tumors, in this difficult to treat disease as this patient had a partial response to single agent gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Duodenal Neoplasms / drug therapy. Purpura, Thrombotic Thrombocytopenic / chemically induced
  • [MeSH-minor] Female. Humans. Middle Aged. Omentum / pathology. Pancreas / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1895-6 [9414181.001]
  • [Cites] Am J Hematol. 2006 Dec;81(12):895-900 [16888787.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):768-76 [16115135.001]
  • [Cites] Ann Hematol. 2005 Feb;84(2):110-4 [15340761.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):634-41 [17613425.001]
  • [Cites] Curr Opin Hematol. 2008 Sep;15(5):445-50 [18695366.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):94-6 [15293577.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):191-201 [9625429.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2826-32 [17026561.001]
  • (PMID = 19967470.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


100. Takase M, Sumiyama Y, Nagao J: Quantitative evaluation of reconstruction methods after gastrectomy using a new type of examination: digestion and absorption test with stable isotope 13C-labeled lipid compound. Gastric Cancer; 2003;6(3):134-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative evaluation of reconstruction methods after gastrectomy using a new type of examination: digestion and absorption test with stable isotope 13C-labeled lipid compound.
  • METHODS: Among patients who had undergone gastrectomy for gastric cancer, 40 patients who had been operated on between 1 and 3 years previously were evaluated.
  • Ten patients had undergone the double-tract (DT) method, and 10 patients had received the Roux-en-Y (RY) method after a total gastrectomy.
  • Twenty patients who had undergone the Billroth I (BI) method after a distal gastrectomy were the control group.
  • RESULTS. The (13)C-trioctanoin test showed, in relation to the reconstruction procedure, the highest average peak of fat absorption in the BI group (which had food passage through the duodenum), followed by the average peak of fat absorption in the DT group and the RY groups.
  • In a comparison of duration, at 60 min and 90 min after administration, the BI group and DT group showed a significantly higher level than the RY group.
  • The peaking time (average time at peak level) showed a significant difference between the RY group and the other groups.
  • CONCLUSION: According to this study, which evaluated fat absorption after different reconstructive procedures after gastrectomy, the procedure that accommodated for the passage of food through the duodenum showed better results for the absorption of medium-chain triglycerides, and the patients also showed a better physiological state.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • Hazardous Substances Data Bank. Tricaprylin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14520525.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caprylates; 0 / Carbon Isotopes; 0 / Dietary Fats; 0 / Triglycerides; 538-23-8 / tricaprylin
  •  go-up   go-down






Advertisement